#### REVIEW



# The influence of telehealth-based cancer rehabilitation interventions on disability: a systematic review

Rachelle Brick<sup>1</sup> · Lynne Padgett<sup>2</sup> · Jennifer Jones<sup>3</sup> · Kelley Covington Wood<sup>4</sup> · Mackenzi Pergolotti<sup>4</sup> · Timothy F. Marshall<sup>5</sup> · Grace Campbell<sup>6,7</sup> · Rachel Eilers<sup>8</sup> · Sareh Keshavarzi<sup>9,10</sup> · Ann Marie Flores<sup>11,12,13</sup> · Julie K. Silver<sup>14,15,16,17</sup> · Aneesha Virani<sup>18</sup> · Alicia A. Livinski<sup>19</sup> · Mohammed Faizan Ahmed<sup>3</sup> · Tiffany Kendig<sup>4</sup> · Bismah Khalid<sup>20</sup> · Jeremy Barnett<sup>21</sup> · Anita Borhani<sup>3</sup> · Graysen Bernard<sup>3</sup> · Kathleen Doyle Lyons<sup>22</sup>

Received: 5 January 2022 / Accepted: 2 February 2022 This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022

#### Abstract

**Purpose** To characterize delivery features and explore effectiveness of telehealth-based cancer rehabilitation interventions that address disability in adult cancer survivors.

**Methods** A systematic review of electronic databases (CINAHL Plus, Cochrane Library: Database of Systematic Reviews, Embase, National Health Service's Health Technology Assessment, PubMed, Scopus, Web of Science) was conducted in December 2019 and updated in April 2021.

**Results** Searches identified 3,499 unique studies. Sixty-eight studies met inclusion criteria. There were 81 unique interventions across included studies. Interventions were primarily delivered post-treatment and lasted an average of 16.5 weeks (SD=13.1). They were most frequently delivered using telephone calls (59%), administered delivered by nursing professionals (35%), and delivered in a one-on-one format (88%). Risk of bias of included studies was primarily moderate to high. Included studies captured 55 measures of disability. Only 54% of reported outcomes had data that allowed calculation of effect sizes ranging -3.58 to 15.66.

**Conclusions** The analyses suggest small effects of telehealth-based cancer interventions on disability, though the heterogeneity seen in the measurement of disability makes it hard to draw firm conclusions. Further research using more diverse samples, common measures of disability, and pragmatic study designs is needed to advance telehealth in cancer rehabilitation. **Implications for Cancer Survivors** Telehealth-based cancer rehabilitation interventions have the potential to increase access to care designed to reduce disability across the cancer care continuum.

Keywords Telehealth · Cancer rehabilitation · Neoplasm · Function · Intervention · Disability

#### Introduction

Cancer-related disability is a pervasive consequence of the disease itself as well as oncology-directed treatment. For the purposes of this paper, cancer-related disability is defined as limitations associated with roles, routines, functional activities, or societal participation [1] or reductions in well-being. Nearly 55% of adult cancer survivors report restrictions in their ability to perform instrumental activities of daily living and 37% report restrictions in their ability to perform basic activities of daily living [2]. Survivors may also experience

Rachelle Brick rachelle.brick@nih.gov significant challenges in returning to employment due to functional limitations [3]. The negative influence of disability spans many different types of cancer [2] and can also affect a person's ability to tolerate cancer-related treatment and health-related quality of life [4].

The multidisciplinary field of cancer rehabilitation seeks to reduce disability and improve functioning among survivors [5]. Evidence from reviews supports the utilization of cancer rehabilitation interventions along the oncology care continuum [6–10]; however, rates of referral and participation are low [11, 12]. Although multifactorial, two factors are consistently implicated in low utilization [12, 13]. First, there are not enough rehabilitation specialists who have expertise in oncology [14]. Second, patients perceive they have limited time and energy to access rehabilitation

Extended author information available on the last page of the article

services, particularly if they need to travel long distances to do so [15].

Telehealth-based cancer rehabilitation interventions may help to overcome patient-, provider-, and health systemrelated barriers which limit access to care [3, 16]. Telehealth is defined as "the delivery of health care services, where distance is a critical factor, by all health care professionals using information and communication technologies, for the exchange of valid information for...treatment, and prevention of disease and injuries, [and] research and evaluation... in all the interests of advancing the health of individuals and their communities" [17, p. 9]. To develop robust cancer rehabilitation programs and train providers in the delivery of interventions, it is important to examine the characteristics and the effectiveness of existing telehealth-based interventions that address disability.

The purpose of this systematic review is to characterize intervention delivery features and evaluate the effectiveness of telehealth-based cancer rehabilitation interventions addressing disability among adult cancer survivors. The results of this systematic review will help to inform future telehealth-based cancer rehabilitation intervention development, testing, and implementation.

#### Methods

A study protocol was developed a priori using the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) checklist [18]. The protocol was registered on PROSPERO (CRD42020150791) prior to data collection. The 2020 PRISMA statement and checklist guided the manuscript development [19].

#### Information sources and search strategy

A biomedical librarian (AAL) developed a comprehensive search strategy in consultation with co-authors. The original search was run in December 2019 and updated in April 2021 using seven citation and abstract databases: CINAHL Plus (Ebscohost), Cochrane Library: Database of Systematic Reviews (Wiley & Sons), Embase (Elsevier), National Health Service's Health Technology Assessment (University of York), PubMed (US National Library of Medicine), Scopus (Elsevier), and Web of Science: Core Collection (Clarivate Analytics). Searches were limited to original research articles and systematic reviews published in English between 1994 and 2021. Keywords and controlled vocabularies (e.g., MeSH, EMTREE, CINAHL Subject Headings) were used to describe telehealth, rehabilitation, and cancer (see Supplementary File Table 1 for final search strategies used). End-Note X9.3.3 (Clarivate Analytics) was used to collect, manage, and identify duplicate citations. Individuals conducting

the study selection process hand searched the bibliographies of literature reviews to identify relevant studies not captured in the search.

#### **Study inclusion**

We initially included studies evaluating cancer rehabilitation interventions that met the following criteria: (1) written in English, (2) had intervention goal(s) included prevention, reduction, or attenuation of decline in disability (i.e., goal of maintaining or improving function in daily roles and routines, preventing or reducing disability, maximizing participation, and/or improving a functional aspect of quality of life); (3) intervention delivered according to the World Health Organization definition of telehealth [17]; (4) included participants with a current or previous cancer diagnosis, (with or without their caregivers); and (5) measured disability, based on the definition by O'Young and colleagues [1], as a primary or secondary outcome. We operationalized the fifth criterion by saying the study needed to measure the impact on function and disability (e.g., social roles, activities of daily living, vocational roles, recreational roles) and/or use of a quality of life measurement tool that assesses ability to function as a component or aspect of quality of life [1]. The initial full text screening revealed a large number of relevant articles (n = 132). To ensure that we were synthesizing literature that addressed our specific research objectives, we added two additional inclusion criteria: (6) utilization of a randomized controlled trial design (to evaluate intervention effectiveness); and (7) inclusion of at least one synchronous interaction between participants and cancer rehabilitation professions (to more closely reflect current billable rehabilitation services).

Studies were excluded if they were as follows: (1) only pharmacological interventions; (2) interventions that addressed solely psychosocial outcomes (e.g., anxiety, depression, distress); (3) measured only impairment-based and symptom severity outcomes; (4) used only qualitative methodology; (5) were any of the following article types: reviews, white papers/editorials, qualitative studies, letters, commentaries, opinions papers, unpublished research; and (6) published prior to 1994.

#### **Selection process**

Prior to the study selection process, a pilot test of the study selection and data extraction process was completed with seven research team members (KDL, RB, LP, KC, GC, TM) on a sample set of four citations provided from the initial literature search. Adaptations were made to the data collection process based upon this pilot testing (e.g., addition of items to extract, ability to select more than one option, addition of fields). Reviewers (RB, KDL, JJ, LP, KC, MP, TM, GC, RE,

JS, AV, AMF, MF, TK, JB) were trained on data screening procedures through group and individual trainings. Team meetings were held twice during the screening process to discuss and clarify screening procedures.

Covidence (Veritas Health Innovation Ltd., Melbourne, Australia) was used to conduct the two-stage screening process. First, the titles and abstracts of articles were uploaded to Covidence and independently screened by a combination of two reviewers (RB, KDL, JJ, LP, KCW, MP, TM, TK, GC, RE, JS, AV, AMF, MF, JB). Disagreements regarding inclusion between reviewers were resolved through discussion between at least two of the senior project authors (KDL, RSB, LP). Next, the full text articles were independently screened by a combination of two reviewers (RB, KDL, JJ, LP, KCW, MP, TM, TK, GC, RE, JS, AV, AMF, MF, JB) using the same eligibility criteria. Disagreements between the two reviewers were resolved by a third reviewer who was blind to the initial reviewers' decisions.

#### **Data collection process**

A combination of two reviewers (RB, KDL, JJ, LP, KC, MP, TM, GC, RE, AMF, MF, BK, JB) independently extracted data from each included article. Extracted data were entered into a custom-designed Qualtrics survey (Qualtrics, Provo, UT). After completing double-data extraction, the pair of reviewers met to resolve any discrepancies. Final extracted data for each article were compiled into a Microsoft Excel spreadsheet to create a database of results. Each included article was assessed for risk of bias by one co-author (KDL, RB, JJ, LP, or RE) using the Cochrane Collaboration's Risk of Bias (ROB 2.0) tool [20]. To gain a better understanding of the breadth of intervention delivery and measurement tools used to examine functional disability, we made an a priori decision to not remove any studies with high risk of bias.

#### Data extraction and analysis

From each article, a combination of two of co-authors (RB, KDL, JJ, LP, KCW, MP, TM, GC, RE, JS, AV, AMF, MF, TK, JB, RE) extracted data pertaining to study designs, sample characteristics, relevant outcome measures (including raw means and standard deviations), and intervention characteristics (see Supplementary File Table 2 for a complete data dictionary). Study design characteristics included primary purpose of study (e.g., feasibility, efficacy or effectiveness, implementation) and primary endpoint. If the authors did not specify a primary endpoint, reviewers selected the assessment that was the closest to the completion of the intervention. Participant characteristics included the following: sex; type(s) of cancer diagnosis; age; race and/or ethnicity; and treatment phase. Telehealth intervention characteristics

included the following: intervention name; brief experimental intervention(s) description(s); name and type of comparison or control intervention, discipline of interventionists, and intervention delivery features (format, duration, frequency, mode, dose, and length of session). When available, reviewers extracted raw means and standard deviations associated with baseline and post-intervention timepoints for all identified measures of disability.

We used descriptive statistics to summarize characteristics of study designs, participant characteristics, relevant outcome measures, and intervention characteristics. Most often, the unit of analysis was the study, for example, when describing the proportion of studies that used one delivery method versus multiple delivery methods or the average duration of each experimental intervention. Additionally, we used the value list for some variables as the unit of analysis, for example, to describe the proportion of telephone delivery included in the grand sum of all delivery methods reported across all studies.

Standardized effect sizes were used to determine the threshold of outcome clinical significance. For studies that reported raw group means and standard deviations at baseline and the study-specific primary endpoint, effect sizes (Cohen's d) were computed using standardized mean differences [21]. Betweengroup effect sizes were estimated by the differences between the intervention mean changes in functional disability in each intervention and control group divided by the pooled standard deviation (SD) at baseline [21]. If the study did not report a primary endpoint, the effect size of the follow-up closest to the post-intervention assessment was selected for comparison to reduce heterogeneity in data collection. Magnitude of effect size was categorized as negligible (< 0.2), small (0.2–0.5), medium (0.5-0.8), or large (>0.8) [21]. Forest plots were developed to illustrate both the data for each specific study and the pooled estimates. A separate forest plot was presented for each subgroup of studies representing the most commonly included outcome measures. The mean difference and 95% confidence interval for each study in intervention and control groups were used to calculate the pooled mean difference. Qstatistics with an  $I^2$  index were used to assess heterogeneity between studies. An  $I^2$  index of 50% or greater and a p value less than 0.1 were taken to indicate significant statistical heterogeneity [22]. In cases of statistical heterogeneity, a random effects model was applied. When there was no evidence of heterogeneity, the results of fixed effects models were presented. Statistical analyses were performed in R (Version 3.6.3) using the META and METASENS packages.

#### Results

#### Literature search and study selection

The literature and hand searches yielded 6,437 records of which 2,938 were duplicates and 3,499 were screened (Fig. 1). After the title and abstract screening was completed, 3,192 records were excluded and 307 proceeded to full text screening. One hundred thirty-two articles were included in the first-level of full-text review. The second level of full-text review specified articles that were randomized controlled trials, synchronously delivered, and administered by a rehabilitation professional. Of the 64 excluded during the second-level of full text screening, 26 were not randomized controlled trials, 21 did not deliver care synchronously, nine did not include a rehabilitation professional, and eight did not focus exclusively on adult cancer survivors. The final sample for analysis included 68 studies.

#### **Risk of bias**

A risk of bias assessment was completed for all included studies utilizing the Cochrane Collaboration's Risk of Bias (ROB 2.0) tool [20]. Studies were assessed across five domains describing bias associated with (1) randomization; (2) effects of intervention assignment; (3) missing outcome(s) data; (4) measurement of outcome; and (5) selection of reported results. Overall risk of bias was rated as low, some concerns, or high. These results are summarized in Supplementary Materials Table 3. Overall, included studies had the following risk of bias ratings: some concerns of bias (n=29, 43%), followed by high concern (n=21, 31%), and low risk of bias (n=18, 26%). Contributors to bias in studies rated as some concern and high concern (n=50) were

#### Fig. 1 PRISMA flow diagram



most commonly: bias in effects of intervention assignment (n=30, 60%) and/or randomization (n=26, 52%), followed by measurement of outcome (n=18, 36%), selection of reported results (n=11, 22%), and/or missing outcome data (n=8, 16%).

#### Study sample and design

Table 1 describes the study samples. Across the 68 studies, sample sizes ranged from seventeen to 641 participants (mean: 154 individuals, SD: 160). Thirty studies (44%) exclusively enrolled females, ten studies (15%) enrolled only males, and the remaining studies (n=28, 41%) enrolled both male and female survivors. Fifty studies (74%) enrolled participants of one cancer type. Within these studies, the three most prominent cancer types were breast (n=30, 60%), prostate (n=8, 16%), and colorectal (n=4, 8%). Diagnoses ranged from one to eleven in studies that did not limit enrollment based on cancer type. Thirty-four of the 68 studies (50%) included participants that were post-primary treatment completion only whereas 23 studies (34%) enrolled patients during active cancer treatment. Only 5 studies (7%)included participants who were in varying phases across the cancer care continuum (e.g., participants currently receiving treatment and post-treatment completion). Of the 38 studies that reported race or ethnicity (56%), study samples were overwhelmingly White, non-Hispanic participants (mean: 81%, SD: 25).

The reported primary purpose of included study designs was to test efficacy or effectiveness (n=49, 72%) followed by feasibility (n=16, 24%), and implementation (n=3, 4%) of an intervention. Thirty-two studies (47%) included a usual care control group, whereas seven studies (10%) used waitlist-controls. The remaining studies (n=29; 43%) included different combinations of active or attention control groups. Studies were conducted in North America (n=39, 57%), Europe (n=13, 19%), Australia (n=10, 15%), and Asia (n=6, 9%).

#### **Intervention delivery features**

Table 2 presents a summary of intervention descriptions and delivery characteristics are presented in Table 2. Most interventions were delivered completely by telehealth methods (n = 44, 65%), although 24 interventions (35%) had an in-person component. Most commonly used intervention delivery methods were telephone calls (n = 61interventions, 90%), additional in-person component (n = 24, 35%), general internet portals (n = 9, 13%), and activity trackers (n = 9, 13%). Regarding the method of delivery, most of the studies used multiple delivery methods (n = 39, 57%) versus one type of delivery method (n = 29, 43%). The number of delivery methods ranged from 1 to 6, with a mean of 2.0 (SD = 1.1). Almost twothirds of the studies (n = 40, 59%) used telephone calls as the only delivery method.

For most studies, the interventions were delivered through one-on-one provider to patient care (n = 59, 88%). Only three studies (4%) used interventions delivered to families or family dyads, three studies (4%) used groups of unrelated people, and three studies used a blend of group and individual interactions (4%). Duration of the interventions ranged from one to 52 weeks, with a mean of 16.5 weeks (SD = 13.1). Most interventions (n = 53, 78%) described a fixed number of interactions between the participant and provider, compared with a variable number of sessions (n = 10, 15%; n = 5unreported, 7%) based on participant need.

Most interventions (n = 39, 57%) were delivered by practitioners in one discipline as opposed to those that involved practitioners from multiple disciplines (n = 12, 18%); not reported by 17, 25\%). The most frequent discipline involved in intervention administration was nursing professionals (n = 24, 35%), followed by health-related research or graduate assistants (n = 10, 15%), physical therapy practitioners (n = 9, 13%), social workers (n = 7, 10%), or psychologists (n = 7, 10%) (see Table 2 for other discipline interventionists).

#### Functional disability outcome measures

The studies examined a variety of outcome measures related to disability and functional aspects of health-related quality of life (see Table 3). Less than half of the studies (n = 32,47%) had a primary outcome measure assessing disability. We extracted data from 55 distinct outcome measures that assessed disability. In many instances, studies reported on specific subscales within the 55 outcome measures rather than composite scores. For example, Scura and colleagues [78] used two subscales of the Functional Assessment of Cancer Therapy-General (FACT-G) as independent outcome measures. If subscales were considered independent measures, the total number of unique outcome measures would be expanded to 84. Outcome tools were primarily self-report (n = 40, 73%) except for those that measured community mobility or community ambulation (n = 15,27%). Community mobility was measured using performance-based measures of disability such as the Six Minute Walk Test. The most commonly reported outcome measures were the Functional Assessment of Cancer Therapy-General (n = 13, 19%), Medical Outcomes Study Short-Form (SF-36)—Physical Functioning Subscale (n = 13, 19%), Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) (n=8, 12%), and European Organisation for Research and Treatment Quality of Life (EORTC QLQC-30)—Physical Functioning Subscale (n=6, 9%).

<b>Table 1</b> Included studies $(n =$	=68) participa	nt characteristics			
Authors, (year)	Sample size	Cancer type(s) included	Treatment status	Age (years), mean (SD)	% White
Abrahams (2017) [23]	132	Breast	Post-treatment	Intervention: 52.5 (8.2)	Not reported
Allard (2007) [24]	117	Breast	During primary treatment	Total sample: 53.6 (10.17)	Not reported
Anderson (2006) [25]	57	Breast, prostate, multiple myeloma, lung	During primary treatment	Total sample: 52	72%
Aranda (2006) [26]	105	Breast	Palliative	Intervention: 57 (median); Control: 55 (median)	Not reported
Ashing (2016) [27]	39	Breast	Post-treatment	Total sample: 55.5 (13.1)	%0
Ashing-Giwa (2008) [28]	23	Cervical	Post-treatment	Total sample: 49.75 (10.9)	Not reported
Badger (2013) [29]	80	Breast	During primary treatment	Total sample: 47.34(10.5)	0%0
Bailey (2004) [30]	39	Prostate	Pre-treatment	Total sample: 75.4	86%
Barsevick (2004) [31]	396	Breast, lung, lymphoma, colorectal, genital (endometrial, ovarian, prostate, testicular)	During primary treatment	Total sample: 56.3 (12.5)	91%
Basen-Engquist (2020) [32]	37	Breast	During primary treatment	Intervention: 49.6 (13.3); Control: 49.2 (9.2)	59%
Bennett (2007) [33]	56	Breast. Other	Post-treatment	Intervention: 55.5 (8.9); Control: 60.1 (11.0)	98%
Bruera (2013) [34]	190	Gastrointestinal, lung, breast, genitourinary, melanoma, hematologic, other	Palliative	Total sample: 57.5 (median), range 24-84	72%
Burns (2017) [35]	82	Head and neck	During primary treatment	Intervention: 64 ( <i>SD</i> 7.58); Control: 65 ( <i>SD</i> 7.45)	Not reported
Chambers (2012) [36]	740	Prostate	Pre-treatment	Age at diagnosis: Intervention: 63.34 (7.59); Control: 63.43 (7.46)	Not reported
Chan (2020) [37]	202	Prostate	During primary treatment, post-primary treatment	Total sample: 70 (median)	92.6%
Cheville (2013) [38]	66	Lung, colorectal	During primary treatment	Intervention group: 63.8 (12.5); Control group: 65.5 (8.9)	100%
Cheville (2018) [39]	516	Stage IIIC or IV solid tumors, multiple myeloma, myelodysplastic syndrome, or Stage IIIC or IV lymphoma were enrolled	During primary treatment	Total sample: 65.6 (11.1)	95.3%
Cheville (2019) [40]	516	"Pathologically confirmed stage IIIC or IV solid or hematologic cancer"	During primary treatment	Total sample: 65.6 (11.1)	Not reported
Chow (2020) [41]	41	Leukemia, lymphoma, other	Post-treatment	Total sample: 45.1 (median)	78%
Clark (2013) [42]	131	Brain, gastrointestinal, head and neck, lung, other	During primary treatment	Total sample: 58.7 (10.6)	97%
Dennett (2018) [43]	46	Breast, prostate, non-Hodgkin's lymphoma, colorectal, gynecological, liver, pancreas, Hodgkin's lymphoma, kidney, lung, acute myeloid leukemia	During primary treatment	Total sample: 59 (12)	Not reported
Djuric (2011) [44]	40	Breast	Pre-treatment	Intervention non-completers 52.0 (6.9); Intervention completers 52.3 (9.5)	%66

Table 1 (continued)					
Authors, (year)	Sample size	Cancer type(s) included	Treatment status	Age (years), mean (SD)	% White
Dong (2019) [45]	50	Breast	Post-treatment	Intervention: 48.00 (5.54); Control: 51.63 (7.49)	Not reported
Dong (2020) [46]	44	Breast	Post-treatment	Intervention: 50.4 (7.4); Control: 52 (8.5)	Not reported
Dos Santos (2020) [47]	167	Breast, digestive, hematologic	Post-treatment	Total sample: 51 (median)	Not reported
Duijts (2012) [48]	422	Breast	Post-treatment	Total sample: 48.2 (5.6)	Not reported
Ferguson (2016) [49]	47	Breast	Post-treatment	Total sample: 54.6 (12.12)	100%
Fjell (2020) [ <b>5</b> 0]	149	Breast	During treatment	Intervention: 48 (10.6); control: 50 (11.6)	Not reported
Freeman (2015) [51]	118	Breast	Post-treatment	Live delivery: 55.44 (8.08); Telemedicine: 55.57 (9.88); Waitlist Ctrl: 55.28 (7.90)	87%
Galiano-Castillo (2017) [52]	81	Breast	Post-treatment	Total sample: 48.3 (8.8)	Not reported
Galiano-Castillo (2016) [53]	81	Breast	Post-treatment	Intervention: 47.4 (9.6); control: 49.2 (7.9)	Not reported
Gell (2020) [54]	99	Breast, cervical, endometrial, lung, leu- kemia, lymphoma, urinary, melanoma, rectal, oral, ovarian, prostate	Post-treatment	Total sample: 61.4 (9.0)	98.5%
Gordon (2015) [55]	410	Colorectal	During primary treatment	Total sample: 66.3 (10.1)	Not reported
Hawkes (2013) [56]	410	Colorectal	Post-treatment	Total sample: 66.35	Not reported
Hawkins (2017) [57]	300	Prostate	During primary treatment	Experimental: 60.71 (7.54) Control 1: 59.44 (6.40); Control 2: 60.53 (7.44);	Not reported
Hayes (2013) [58]	194	Breast	During primary treatment	Not reported	Not reported
Hegel (2011) [59]	29	Breast	During primary treatment	Total sample: 52.6 (9.4)	100%
Hung (2014) [60]	37	Lymphoma, myeloma	Post-treatment	Intervention: 57.5 (9.8); Usual care: 59.9 (9.2)	Not reported
Jensen (2012) [61]	95	Prostate	Post-treatment	Intervention: 64.1 (62.5–65.8); Control: 62.5 (60.9–64.2)	Not reported
Kelleher (2021) [62]	31	Colorectal	Post-treatment	Total sample: 59.6 (10.5)	96.8%
Kim (2020) [63]	326	Breast	During treatment	Total sample: 52	87.0%
Koller (2018) [64]	39	Gastrointestinal, breast, gynecological, lung, multiple myeloma, other	Palliative	Total sample: 56.6 (10.6)	Not reported
Lahart (2016) [65]	80	Breast cancer	Post-treatment	Total sample: 53.6 (9.4)	78%
Lee (2019) [ <b>66</b> ]	96	Prostate	Post-treatment	Intervention: 69.06 (7.21); Control: 69.82 (7.73)	Not reported
Ligibel (2012) [67]	121	Breast, colon, rectal	Post-treatment	Total sample: 54 (995)	91.7%
Meneses (2020) [68]	432	Breast	Post-treatment	Not reported	94.2%
Meneses (2018) [69]	40	Breast	Post-treatment	Total sample: 56.63 (10.26)	62.5%
Meneses (2009) [70]	53	Breast	Post-treatment	Total sample: 53.58 (11.55)	94.3%

Authors, (year)	Sample size	Cancer type(s) included	Treatment status	Age (years), mean (SD)	% White
Meneses (2007) [71]	256	Breast	Post-treatment	Total sample: 54.5 (11.58)	82%
Morey (2009) [72]	641	Breast, colorectal, prostate	Post-treatment	Intervention 73.0 (5.0); Control 73.1 (5.1)	89%
Pinto (2005) [73]	86	Breast	Post-treatment	Total sample: 53.42 (9.08)	96.4%
Pinto (2013) [74]	192	Breast	Post-treatment	Total sample: 60.0 (9.9)	93.8%
Pinto (2013) [75]	46	Colorectal	Post-treatment	Total sample: 57.3 (9.7)	98%
Raphaelis (2020) [76]	153	Gynecological, gastrointestinal, ears, nose, throat, lung, hematological, bone, breast, Other	During treatment and post-treatment	Intervention: 58.6; Control: 58.9	
Sajid (2016) [77]	19	Prostate	During primary treatment	Total sample: 70	73.7%
Scura (2004) [78]	17	Prostate	Pre-treatment	Total sample: 66 (8.3)	59%
Silvers (2014) [79]	21	Esophageal, stomach	Pre-treatment	Intervention: 72 (12); Control: 64 (14)	Not reported
Sui (2020) [80]	200	Lung	During treatment and post-treatment	Intervention: 61.37 (11.21); Control: 62.35 (9.98)	Not reported
Syrjala (2018) [81]	337	Acute leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, myelodysplasias, multiple myeloma, Hodgkin's lymphoma, other	Post-treatment	Total sample: 51 (12)	94%
Temur (2019) [82]	61	Breast	Post-treatment	Intervention group: 47.6 (8.96); Control group: 45.6 (9.03)	Not reported
Vallerand (2018) [83]	51	Leukemia, Hodgkin's lymphoma, non- Hodgkin's lymphoma	During primary treatment	Total sample: 52.6 (13.7)	Not reported
Waller (2021) [84]	22	Abdominal	Pre-treatment	Intervention: 55.5; Control: 61	Not reported
Wang (2019) [85]	60	Oral	During primary treatment	Total sample: 55.98 (11.73)	Not reported
Wenzel (2015) [86]	204	Cervical	Post-treatment	Total sample: 43	51.4%
Yanez (2015) [87]	74	Prostate	During primary treatment	Total sample: 68.84 (9.23)	56.8%
Yates (2005) [88]	109	Breast	During primary treatment	Total sample: 49.4 (9.4)	Not reported
Zhang (2015) [89]	244	Prostate	Post-treatment	Support group: 66.8 (7.2); Telephone group: (64.3 (7.3); Control: 64.9 (8.2)	62.7%
Zhou (2020) [90]	111	Breast	Pre-treatment and during primary treatment	Intervention: 49.84 (8.85)	Not reported

Table 2 Summary of interv	vention description and delive	ery features				
Author (year)	Brief intervention description	Mode of delivery	Format	Duration and frequency of intervention	Interventionist (disci- pline)	Comparison condition(s)
Abrahams (2017) [23]	Cognitive-behavioral model of face-to-face and web-based modules reviewing precipitating and perpetuating factors of fatigue	General internet portal; Telephone calls; In-person	Individual	24 weeks Fixed Interactions: 3	Psychology	Wait list
Allard (2007) [24]	Psychoeducational telephone intervention designed to help women direct their focus of attention toward the functional pathway of coping	Telephone calls	Individual	2 weeks Fixed Interactions: 2	Nursing	Usual care
Anderson (2006) [25]	20-min audiotape included positive mood statements and positive imagery suggestions	Telephone calls	Individual	2 weeks Not reported Nurses called ''periodi- cally''	Nursing	Distraction audiotape; Relaxation audiotape; Wait list
Aranda (2006) [26]	Cognitive-behavioral techniques and educa- tion	Telephone calls	Family dyad or group	1 week Fixed Interactions: 2	Nursing	Usual care
Ashing (2016) [27]	Psychoeducation	Telephone calls	Individual	16 weeks Fixed Interactions: 8	Health-related Research Assistant	Usual care
Ashing-Giwa (2008) [28]	Problem-focused Cogni- tive Behavioral Therapy	Telephone calls	Individual	12 weeks Fixed Interactions: 6	Health-related Research Assistant	Usual care
Badger (2013) [29]	Enhancing emotional support both through the direct effects of the interaction with the interventionist and mobilizing the survivors' naturally occurring support	Telephone calls	Family dyad or group	8 weeks Fixed Interactions: 8	Social Work	Telephone health education
Bailey (2004) [30]	Watchful waiting intervention to manage uncertainty via cogni- tive reframing	Telephone calls	Individual	5 weeks Fixed Interactions: 5	Nursing	Usual care
Barsevick (2004) [31]	Energy conservation and activity management	Telephone calls	Individual	3 weeks Fixed Interactions: 3	Nursing	Attention control (informa- tion on nutrition)
Basen-Engquist (2020) [32]	To educate and enhance self-efficacy in the size acceptance approach	Telephone calls	Individual	25 weeks Fixed Interactions: 20	Masters-level Health Educators	Usual care

Table 2 (continued)						
Author (year)	Brief intervention description	Mode of delivery	Format	Duration and frequency of intervention	Interventionist (disci- pline)	Comparison condition(s)
Bennett (2007) [33]	Motivational interview- ing to facilitate 30 daily minutes of moderate to vigorous physical activity	Telephone calls	Hybrid	16 weeks Fixed Interactions: 4	Social Work	Two phone calls (brief, social conversations)
Bruera (2013) [34]	Methylphenidate + nurs- ing phone intervention	Telephone calls	Individual	2 weeks Variable	Nursing	Methylphenidate + con- trol phone interven- tion; Placebo + nursing phone intervention; Placebo + control phone intervention
Burns (2017) [ <b>35</b> ]	Speech pathology tel- epractice	Video Conferencing; Telephone calls; In- Person; Other	Individual	Not reported	Speech Language Pathol- ogy	Usual care
Chambers (2012) [36]	Psycho-education, stress management, coaching, decision support and cognitive reframing	Telephone calls	Individual	20 weeks Fixed Interactions: 5	Nursing	Usual care
Chan (2020) [37]	Web-based behavio- ral support with two optional calls with dietician and/or exercise physiologist	General Internet Portal; Telephone calls; Activity tracker; Text	Individual	12 weeks Variable 4 interactions (2 optional calls)	Dietetics; Exercise Physi- ology	Level 1: General informa- tion and guidelines via website; Level 2: Level 1 plus personalized diet and exercise prescriptions and videos and survey about progress; Level 3: Level 2 plus Fitbit Alta with physical activ- ity reports and supportive text messages
Cheville (2013) [38]	Exercise plus pedometer- based walking program	Telephone calls; In-Person	Individual	8 weeks Fixed Interactions: 5	Physical Therapy	Usual care
Cheville (2018) [39]	Three Component Model (TCM)-Rehabilitation Services plus con- ventional TCM pain management	Telephone calls; Activity trackers	Individual	26 weeks Fixed Interactions: 8	Physical Therapy; Nursing; MD	Three component model rehabilitation; Exercise plus pedometer
Cheville (2019) [40]	Telerehabilitation with pharmacological pain management arm	General internet portal; Telephone calls; Activity tracker; In-person	Individual	24 weeks Variable	Physical Therapy; Nursing; MD	Usual care

	description		Format	Duration and frequency of intervention	Interventionist (disci- pline)	Comparison condition(s)
Chow (2020) [41]	Mobile health supported intervention to improve diet and physical activ- ity	Telephone calls; Text-messaging; General internet portal; Activity Tracker; Facebook group; Mobile application	Individual	16 weeks Fixed Interactions: # not reported	Health-related Research Assistant	Access to the Fitbit tracker and Healthwatch360 app
Clark (2013) [42]	Multi-disciplinary coun- seling intervention to maintain quality of life	Telephone calls	Hybrid	27 weeks Fixed Interactions: 17	Physical Therapy; Psychology; Social Work; Nursing	Usual care
Dennett (2018) [43]	Motivational interviewing plus aerobic and resist- ance exercise, individual and group education	Telephone calls	Individual	7 weeks Fixed Interactions: 7	Physical Therapy	Oncology rehabilitation of exercise and education
Djuric (2011) [44]	Motivational interview- ing; Education and counseling	Telephone calls	Individual	52 weeks Variable	Dietetics	Education, pedometer, log, newsletters
Dong (2019) [45]	Remotely-guided muscle training, endurance training, and education	Video Conferencing; Instant Messaging or Texting; Mobile Application; Activity Tracker	Individual	12 weeks Fixed Interactions: 84	Physical Therapy	Usual care (traditional rehabilitation)
Dong (2020) [46]	Remotely-guided muscle training, endurance training, and education	Video Conferencing; Instant Messaging or Texting; Mobile Application; Activity Tracker	Individual	12 weeks Fixed Interactions: 84	Physical Therapy	Usual care (traditional rehabilitation)
Dos Santos (2020) [47]	Computer-Assisted Cog- nitive Rehabilitation	Other (computer pro- gram)	Individual	12 weeks Fixed Interactions: 9	Neuropsychology	Telephone calls; Cognitive exercises at home via workbook
Duijts (2012) [48]	Cognitive Behavioral Therapy and relaxation exercises	Telephone calls; In-person	Group	6 weeks Fixed Interactions: 6	Physical Therapy; Psychology; Social Work	Physical exercise
Ferguson (2016) [49]	Cognitive Behavioral Therapy	Video conferencing	Individual	8 weeks Fixed Interactions: 8	Psychology	Behavioral placebo (sup- portive therapy)
Fjell (2020) [50]	Interaktor: Real-time can- cer sequelae monitoring	Text messaging; Mobile Application; Telephone calls; In-person	Individual	18 weeks Variable	Nursing; Health-related Research Assistant	Usual care

Table 2 (continued)

Table 2 (continued)						
Author (year)	Brief intervention description	Mode of delivery	Format	Duration and frequency of intervention	Interventionist (disci- pline)	Comparison condition(s)
Freeman (2015) [51]	Education; mind-body connection; imagery techniques	Video Conferencing; Telephone Calls	Group	17 weeks Fixed Interactions: 17	Social Work; Medical Physician	In-person delivery
Galiano-Castillo (2017) [52]	Tailored exercise program	Video Conferencing; General Internet Portal; Instant Messaging or Texting; Telephone calls	Individual	8 weeks Fixed Interactions: 24	Not specified	Education regarding health benefits of physical activity: Written general exercise guidelines
Galiano-Castillo (2016) [53]	Online system that facilities remote reha- bilitation and consists of public and private interfaces with updated information about breast cancer	Video Conferencing; General Internet Portal; Instant Messaging or Texting; Telephone calls	Individual	8 weeks Fixed Interactions: 24	Not specified	Written recommendations
Gell (2020) [54]	Health coaching	Instant Messaging or Texting; Telephone calls; Activity Tracker	Individual	8 weeks Fixed Interactions: 4	Not specified	Fitbit only
Gordon (2015) [55]	Health coaching	Telephone calls	Individual	24 weeks Fixed Interactions: 11	Not specified	Usual care
Hawkes (2013) [56]	Health coaching	Telephone calls	Individual	24 weeks Fixed Interactions: 12	Psychology; Nursing; Health-related Research Assistant	Usual care
Hawkins (2017) [57]	Comprehensive Health Enhancement Support System + Mentor	Telephone calls	Individual	24 weeks Fixed Interactions: 10	Human Cancer Informa- tion Mentor	Mentor only; CHESS only
Hayes (2013) [58]	Exercise	Telephone calls	Individual	32 weeks Fixed Interactions: 16	Exercise Physiologist	Telephone delivered exer- cise intervention; Usual care
Hegel (2011) [59]	Cognitive Behavioral Therapy	Telephone calls	Individual	6 weeks Fixed Interactions: 6	Occupational Therapy	Usual care
Hung (2014) [60]	Nutrition and exercise counseling	Telephone calls	Individual	12 weeks Variable	Dietetics; Exercise Physiology	Usual care
Jensen (2012) [61]	Telephone consultation	Telephone calls	Individual	1 week Fixed Interactions: 1	Nursing	Usual care
Kelleher (2021) [62]	Coping skills training	Telephone calls	Individual	5 weeks Fixed Interactions: 5	Health-related Research Assistant	Usual care

Author (pear)DerivationMode of deliveryFerrationDerivation and FequencyInterventioning (disc).ComparisonKin (2000) (63)ExhinancemontTelephone callsIndividual24 weeksConcertification Spc.Interventioning Spc.Interventioning Spc.Interventioning Spc.Kolter (2018) (64)ExhinancemontTelephone callsIndividual24 weeksConcertification Spc.Interventioning Spc.Interventioning Spc.Interventioning Spc.Kolter (2018) (64)ExhinancemontTelephone callsIndividual24 weeksNursingUsal careKolter (2018) (64)ExherciseTelephone callsIndividual24 weeksNursingUsal careLahart (2016) (65)Pysisual activity comTelephone callsIndividual24 weeksNursingUsal careLahart (2012) (67)ExerciseTelephone callsIndividual24 weeksNursingUsal careLahart (2016) (65)ExerciseTelephone callsIndividual24 weeksNursingUsal careLahart (2016) (65)ExerciseTelephone callsIndividual24 weeksNursingUsal careLahar	Table 2 (continued)						
Kun (2000) (51)         Comprehensive Health Inhumer Support System + Amener Support System + Amener Differencies (2010) [65]         Constrestime Support System + Amener Support System + Amener Support System + Amener Differencies (2012) [65]         Cancer Information System - Support System - Support Differencies (2012) [65]         Cancer Information System - Support System - Support (2012) [65]         Cancer Information System - Support System - Support Differencies (2012) [65]         Cancer Information System - Support System - Support (2012) [65]         Cancer Information System - Support (2012) [66]         Cancer Information System - Support (2012) [67]         Cancer Information System - Support (2012) [68]         Information - Support (2012) [68] <thinter -="" support<br="">(20</thinter>	Author (year)	Brief intervention description	Mode of delivery	Format	Duration and frequency of intervention	Interventionist (disci- pline)	Comparison condition(s)
Koller (2018) (54)Education, skill building.Telephone calls: net oreching supportIndividualCoveeksNursingUsual care to trajorateLahur (2016) (56)Physical activity countTelephone calls: in Preson:Individual24 weeksNot specifiedUsual careLae (2019) (56)ExerciseTelephone calls: in Preson:Individual12 weeksNot specifiedUsual careLae (2012) (56)ExerciseTelephone calls: otherIndividual12 weeksNot specifiedUsual careLae (2012) (56)ExerciseTelephone calls: otherIndividual12 weeksNot specifiedUsual careLae (2012) (56)ExerciseTelephone calls: otherIndividual12 weeksNor specifiedUsual careMenses (2020) (58)Education and supportTelephone calls: in preson:Individual3 weeksNor specifiedWait IstMenses (2018) (59)Education and apportTelephone calls: in preson:Individual3 weeksNor specifiedWait IstMenses (2018) (59)Education and apportTelephone calls: in preson:Individual3 weeksNor specifiedWait IstMenses (2017) 11Psycheducation and in preson:Telephone calls: individualIndividual3 weeksNor specifiedWait IstMenses (2005) (71)Psycheducation and in preson:Telephone calls: individualIndividual3 weeksNor specifiedWait IstMenses (2005) (71)Psycheducation and in prer	Kim (2020) [63]	Comprehensive Health Enhancement Support System + Mentor	In-Person; General Internet Portal; Telephone calls	Individual	24 weeks Fixed Interactions: 10	Cancer Information Spe- cialist Mentor	Internet access with list of websites; Comprehensive Health Enhancement Support System—Information and Support (CHESS-IS)
Lahart (2016) (65)         Physical activity coun- seling         Telephone calls: network         Individual         24 weeks         Not specified         Usual care value           Le (2019) (66)         Exercise         Telephone calls: not other         Individual         12 weeks         Medical Physician         Pedometer           Lighel (2012) (67)         Exercise         Telephone calls: not other         Individual         12 weeks         Medical Physician         Pedometer           Lighel (2012) (67)         Exercise         Telephone calls: not other         Individual         12 weeks         Not specified         Usual care           Meneses (2020) (88)         Education and support         Telephone calls: Individual         Individual         52 weeks         Not specified         Wait list           Meneses (2009) [70]         Psychoeducation and support         Telephone calls: Individual         Individual         3 weeks         Not specified         Wait list           Meneses (2009) [71]         Psychoeducation and support         Telephone calls: Individual         Individual         3 weeks         Not specified         Wait list           Meneses (2009) [71]         Psychoeducation and support         Telephone calls: Individual         Individual         3 weeks         Not specified         Wait list           Meneses (2009) [72]<	Koller (2018) [64]	Education, skill building, and coaching to support self-management	Telephone calls; In-person	Individual	6 weeks Not reported	Nursing	Usual care
Lee (2019) [66]         Exercise         Telephone cells:         Individual         12 weeks         Medical Physician         Pedometer           Lighel (2012) [67]         Exercise         Telephone cells:         Individual         10 weeks         Social Work         Usual care           Meneses (2020) [68]         Education and support         Telephone cells:         Individual         10 weeks         Social Work         Usual care           Meneses (2020) [68]         Education and support         Telephone cells:         Individual         50 weeks         Social Work         Usual care           Meneses (2018) [69]         Education and support         Telephone cells:         Individual         3 weeks         Nursing         Mai list           Meneses (2007) [71]         Psychoeducation and         Telephone cells:         Individual         3 weeks         Nursing         Wait list           Meneses (2007) [71]         Psychoeducation and         Telephone cells:         Individual         3 weeks         Nursing         Wait list           Meneses (2007) [71]         Psychoeducation and         Telephone cells:         Individual         3 weeks         Nursing         Wait list           Meneses (2007) [71]         Psychoeducation and         Telephone cells:         Individual         3 weeks <td< td=""><td>Lahart (2016) [65]</td><td>Physical activity coun- seling</td><td>Telephone calls; In-Person; Other</td><td>Individual</td><td>24 weeks Not reported</td><td>Not specified</td><td>Usual care</td></td<>	Lahart (2016) [65]	Physical activity coun- seling	Telephone calls; In-Person; Other	Individual	24 weeks Not reported	Not specified	Usual care
Ligibel (2012) [67]ExerciseTelephone callsIndividual16 weeksSocial WorkUsual careMeneses (2020) [68]Education and supportTelephone calls;Individual22 weeksNursingDelayed supMeneses (2020) [68]Education and supportTelephone calls;Individual32 weeksNursingDelayed supMeneses (2020) [70]Education and supportTelephone calls;Individual32 weeksNot specifiedWait listMeneses (2000) [70]Psychoeducation andTelephone calls;Individual38 weeksNot specifiedWait listMeneses (2000) [70]Psychoeducation andTelephone calls;Individual28 weeksNursingWait listMeneses (2000) [70]Psychoeducation andTelephone calls;Individual28 weeksNursingWait listMeneses (2000) [71]Psychoeducation andTelephone calls;Individual28 weeksNursingWait listMeneses (2000) [71]Psychoeducation andTelephone calls;Individual24 weeksNursingWait listMorey (2000) [72]Counseling and educationTelephone calls;Individual23 weeksNursingWait listMorey (2000) [73]Physical activity coun-Telephone calls;Individual23 weeksNursingWait listMorey (2000) [73]Physical activity coun-Telephone calls;Individual12 weeksNursingMait listPino (2013) [74]Advice and counselingTelephone calls;Individu	Lee (2019) [66]	Exercise	Telephone calls; Mobile Application; Other	Individual	12 weeks Not reported	Medical Physician	Pedometer
Meneses (2020) [68]         Education and support In person;         Individual         52 weeks         Nursing         Delayed sup Harea fixed Interactions: 11           Meneses (2018) [69]         Education         Telephone calls;         Individual         52 weeks         Nursing         Delayed sup           Meneses (2009) [70]         Education         Telephone calls;         Individual         3 weeks         Not specified         Wait list           Meneses (2009) [70]         Psychoeducation and         Telephone calls;         Individual         28 weeks         Nursing         Wait list           Meneses (2007) [71]         Psychoeducation and         Telephone calls;         Individual         24 weeks         Nursing         Wait list           Morey (2009) [72]         Counseling and education         Telephone calls;         Individual         24 weeks         Nursing         Wait list           Fixed Interactions: 15         Physical activity coun-         Telephone calls;         Individual         24 weeks         Norsing         Wait list           Fixed Interactions: 15         Physical activity coun-         Telephone calls;         Individual         24 weeks         Norsing         Wait list           Fixed Interactions: 16         Connseling and education         Telephone calls;         Individual         2	Ligibel (2012) [67]	Exercise	Telephone calls	Individual	16 weeks Variable 10–11 interactions	Social Work	Usual care
Meneses (2018) [69]         Education         Telephone calls;         Individual         3 weeks         Not specified         Wait list           Meneses (2009) [70]         Psychoeducation and         Telephone calls;         Individual         3 weeks         Not specified         Wait list           Meneses (2007) [71]         Psychoeducation and         Telephone calls;         Individual         28 weeks         Nursing         Wait list           Meneses (2007) [71]         Psychoeducation and         Telephone calls;         Individual         24 weeks         Nursing         Wait list           Morey (2009) [72]         Counseling and education         Telephone calls;         Individual         24 weeks         Nursing         Wait list           Morey (2009) [72]         Counseling and education         Telephone calls;         Individual         24 weeks         Norsing         Wait list           Morey (2009) [72]         Counseling and education         Telephone calls;         Individual         12 weeks         Social Work         Wait list           Pinto (2005) [73]         Physical activity coun-         Telephone calls;         Individual         12 weeks         Social Work         Contact cor           Pinto (2005) [74]         Advice and counseling         Telephone calls;         Individual         12	Meneses (2020) [68]	Education and support	Telephone calls; In person; Mail	Individual	52 weeks Fixed Interactions: 11	Nursing	Delayed support
Meneses (2009) [70]Psychoeducation and supportTelephone calls; In-personIndividual28 weeks Fixed Interactions: 8Nursing Wait list Wait listMeneses (2007) [71]Psychoeducation and supportTelephone calls; In-personIndividual24 weeks Fixed Interactions: 8Nursing Wait list Fixed Interactions: 9Wait list Wait list Fixed Interactions: 9Morey (2009) [72]Psychoeducation and supportTelephone calls; In-personIndividual24 weeks Fixed Interactions: 9Wait list Wait list Fixed Interactions: 9Pinto (2005) [73]PsychoeducationTelephone calls; IndividualIndividual12 weeksSocial Work Social WorkWait list Wait list Fixed Interactions: 15Pinto (2013) [74]Advice and counseling Advice and counselingTelephone calls; In-Person;Individual12 weeksNot specifiedAdvice plus Advice plusPinto (2013) [75]Physical activityTelephone calls; In-Person;Individual12 weeksNot specifiedAdvice plusPinto (2013) [75]Physical activityTelephone calls; IndividualIndividual	Meneses (2018) [69]	Education	Telephone calls; Other	Individual	3 weeks Fixed Interactions: 9	Not specified	Wait list
Meneses (2007) [71]Psychoeducation and supportTelephone calls; In-personIndividual24 weeksNursingWait listMorey (2009) [72]Counseling and educationTelephone callsIndividual52 weeksSocial WorkWait listMorey (2005) [73]Physical activity coun- selingTelephone calls; In-personIndividual52 weeksSocial WorkWait listPinto (2005) [73]Physical activity coun- selingTelephone calls; In-personIndividual12 weeksHealth-related ResearchContact cordPinto (2013) [74]Advice and counselingTelephone calls; In-PersonIndividual12 weeksNot specifiedAdvice plusPinto (2013) [75]Physical activityTelephone calls; In-Person;Individual12 weeksNot specifiedAdvice plusPinto (2013) [75]Physical activityTelephone calls; In-Person;Individual12 weeksNot specifiedAdvice plusPinto (2013) [75]Physical activityTelephone calls; In-Person;Individual12 weeksNot specifiedSymptom side of the searchPinto (2013) [75]Physical activityTelephone calls; In-Person;Individual12 weeksNot specifiedSymptom side of the searchSymptom side of the searchPinto (2013) [75]Physical activityTelephone calls; In-Person;Individual12 weeksNot specifiedSymptom side of the searchSymptom side of the searchPinto (2013) [75]Physical activityTelephone calls; Inverson; <t< td=""><td>Meneses (2009) [70]</td><td>Psychoeducation and support</td><td>Telephone calls; In-person</td><td>Individual</td><td>28 weeks Fixed Interactions: 8</td><td>Nursing</td><td>Wait list</td></t<>	Meneses (2009) [70]	Psychoeducation and support	Telephone calls; In-person	Individual	28 weeks Fixed Interactions: 8	Nursing	Wait list
Morey (2009) [72]Counseling and educationTelephone callsIndividual52 weeksSocial WorkWait listPinto (2005) [73]Physical activity coun-Telephone calls;Individual12 weeksHealth-related ResearchContact corPinto (2005) [73]Physical activity coun-Telephone calls;Individual12 weeksHealth-related ResearchContact corPinto (2013) [74]Advice and counselingTelephone calls;Individual12 weeksNot specifiedAdvice plusPinto (2013) [75]Physical activityTelephone calls;Individual12 weeksNot specifiedAdvice plusPinto (2013) [75]Physical activityTelephone calls;Individual12 weeksNot specifiedSymptom siPinto (2013) [75]Physical activityTelephone calls;Individual12 weeksSymptoms: 8Advice plus	Meneses (2007) [71]	Psychoeducation and support	Telephone calls; In-person	Individual	24 weeks Fixed Interactions: 9	Nursing	Wait list
Pinto (2005) [73]Physical activity coun- selingTelephone calls; Activity Tracker;Individual12 weeksHealth-related ResearchContact corn-personIn-personFixed Interactions: 15AssistantAdvice plusPinto (2013) [74]Advice and counselingTelephone calls;Individual12 weeksNot specifiedAdvice plusPinto (2013) [75]Physical activityTelephone calls;Individual12 weeksNot specifiedSymptom siPinto (2013) [75]Physical activityTelephone calls;Individual12 weeksSymptom si	Morey (2009) [72]	Counseling and education	Telephone calls	Individual	52 weeks Fixed Interactions: 15	Social Work	Wait list
Pinto (2013) [74]Advice and counselingTelephone calls;Individual12 weeksNot specifiedAdvice plu:In-Person;In-Person;Fixed Interactions: 8Advice plu:OtherOtherIn-Verson;Individual12 weeksHealth-related ResearchSymptom sinteractions: 12Pinto (2013) [75]Physical activityTelephone calls;Individual12 weeksHealth-related ResearchSymptom sinteractions: 12	Pinto (2005) [73]	Physical activity coun- seling	Telephone calls; Activity Tracker; In-person	Individual	12 weeks Fixed Interactions: 15	Health-related Research Assistant	Contact control
Pinto (2013) [75] Physical activity Telephone calls; Individual 12 weeks Health-related Research Symptom si Fixed Interactions: 12 Assistant	Pinto (2013) [74]	Advice and counseling	Telephone calls; In-Person; Other	Individual	12 weeks Fixed Interactions: 8	Not specified	Advice plus contact control
	Pinto (2013) [75]	Physical activity	Telephone calls; In-Person;	Individual	12 weeks Fixed Interactions: 12	Health-related Research Assistant	Symptom surveys

Table 2 (continued)						
Author (year)	Brief intervention description	Mode of delivery	Format	Duration and frequency of intervention	Interventionist (disci- pline)	Comparison condition(s)
Raphaelis (2020) [76]	Self-management support	Telephone calls; In-Person	Family Dyad or Group	Not specified Variable (based on pain intensity; maximum of 4 interactions)	Nursing	Usual care
Sajid (2016) [77]	Home-based walking and exercise	Telephone calls; Activity Tracker; In-person	Individual	6 weeks Fixed Interactions: 6	Exercise Physiology	Wii-fit; Usual care
Scura (2004) [78]	Support and education	Telephone calls; Other	Individual	52 weeks Fixed Interactions: 25	Nursing; Health-related Research Assistant	Education
Silvers (2014) [79]	Nutrition education and behavior change tech- niques	Telephone calls; In-person	Individual	26 weeks Fixed Interactions: 19	Not specified	Standard care
Sui (2020) [80]	WeChat app-based educa- tion and rehabilitation	Mobile App; In-person	Individual	52 weeks Fixed Interactions: 130	Nursing	One education session with telephone follow-up as needed
Syrjala (2018) [81]	Education, resources and Cognitive Behavioral Therapy	General Internet Portal; Telephone calls	Individual	24 weeks Variable	Psychology	Education and resources; Wait list
Temur (2019) [82]	Self-management for lymphedema using exercises and lymphatic drainage	Telephone calls; In-person	Individual	24 weeks Fixed Interactions: 6	Health-related Research Assistant	Usual care
Vallerand (2018) [83]	Counseling	Telephone calls	Individual	12 weeks Fixed Interactions: 12	Not specified	Written guidelines and goal
Waller (2021) [84]	Trimodal prehabilitation to promote physical activity, nutrition, and psychological well- being	Mobile Application; Activity Tracker; Telephone calls	Individual	Two weeks Variable	Physical Therapy	Usual care
Wang (2019) [85]	Support and monitoring	Telephone calls; In-person	Individual	12 weeks Fixed Interactions: 6	Nursing	Education pamphlet
Wenzel (2015) [86]	Psychosocial counseling	Telephone calls	Individual	9 weeks Fixed Interactions: 6 interactions	Not specified	Usual care
Yanez (2015) [87]	Cognitive behavioral stress management treatment	Video Conferencing; General Internet Portal	Group	10 weeks Fixed Interactions: 10	Occupational Therapy	Attention control of health promotion
Yates (2005) [88]	Psychoeducation	Telephone calls; In-person	Individual	3 weeks Fixed Interactions: 3	Nursing	General cancer education

Author (year)	Brief intervention description	Mode of delivery	Format	Duration and frequency of intervention	Interventionist (disci- pline)	Comparison condition(s)
Zhang (2015) [89]	Biofeedback exer- cise + support group	Telephone calls; In-person	Hybrid	12 weeks Fixed Interactions: 7	Psychology; Nursing	Exercise + telephone sup- port; Usual care
Zhou (2020) [90]	WeChat app-based educa- tion and rehabilitation	Mobile application; In-person	Individual	26 weeks Fixed Interactions: 182	Medical Physician; Nursing; Health-related Research Assistant	Usual care

Table 2 (continued)

#### **Estimated effect sizes**

On average, the studies reported on 3.1 functional outcomes (range: 1–11 outcomes) for a total of 253 outcomes across 68 studies. Data to calculate between-group effect sizes was available for 154 (54%) of available outcomes (see Table 3). Effect sizes ranged from – 3.58 (clinically meaningful outcomes favoring control intervention) to 15.66 (highly clinically meaningful outcomes favoring the experimental intervention). Given the multitude of outcome measures, we further analyzed the four most used outcome measures to examine influence of telehealth-based cancer rehabilitation interventions on disability (see Fig. 2 for associated forest plots).

#### FACT-G

Of the thirteen articles contained the FACT-G, only seven articles contributed to the analysis. Two articles [25, 47] were comparative effectiveness studies as represented by two or more contrasts in Fig. 2. Heterogeneity across studies was not detected ( $l^2 = 34\%$ ; p = 0.14); however, the interventions varied in content and delivery. The ten interventions represented had a small clinically meaningful effect on overall health-related quality of life (*SMD*: 0.2, CI: 0.0–0.3).

#### SF-36—physical functioning

Thirteen articles contained the SF-36 Physical Functioning subscale. Eight articles, representing ten distinct interventions, contributed to the pooled outcome. Heterogeneity across studies was detected ( $l^2 = 98\%$ ; p < 0.001). Non-significant clinical reductions in perceived physical well-being favored the intervention; however, these were not significant (*SMD*: 0.3, CI: -0.4 to 1.0).

#### FACIT-F

Of the eight articles used the FACIT-F, only three articles contributed to the pooled outcome. The three articles represented four distinct interventions. Heterogeneity across studies was detected ( $I^2 = 81\%$ ; p < 0.001). The pooled outcome revealed a significant decrease in interference of fatigue on health-related quality of life (*SMD*: 0.8, CI: 0.3–1.4).

#### EORTC QLQC-30—physical functioning subscale

Of the six articles contained the EORTC QLQC-30—Physical Functioning Subscale, only four articles contributed to the pooled outcome. Heterogeneity across studies was detected ( $I^2 = 55\%$ ; p < 0.09). The pooled outcome revealed a significant improvement perceived physical well-being (*SMD*: 0.5, CI: 0.1–0.9) among the available data.

#### Table 3 Summary of functional outcome measures and effect size ranges

Outcome tool	Number of articles including outcome tool	Number of articles with available effect sizes ( <i>d</i> )	Range of effect sizes
Functional Assessment of Cancer Therapy— General (FACT-G)	13 [25, 27, 28, 38, 42, 44, 47, 62, 86–88]	7 [25, 27, 38, 42, 47, 62, 88]	-0.67 to 0.8
FACT-G – Physical Well-Being Subscale	2 [47, 78]	1 [47]	-0.22 to $-0.16$
FACT-G – Social Well-Being Subscale	1 [47]	1 [47]	-0.10 to 0.22
FACT-G – Emotional Well-Being Subscale	1 [47]	1 [47]	0.13-0.29
FACT-G – Functional Well-Being Subscale	3 [47, 49, 78]	2 [47, 49]	0.18-0.3
Medical Outcomes Study Short-Form (SF-36) - Total Score	6 [45, 55, 56, 59, 68, 83]	3 [45, 55, 83]	0.63-15.66
SF- 36—Physical Functioning Subscale	13 [32, 33, 36, 46, 48, 68, 69, 71, 75, 81]	8 [32, 33, 36, 46, 48, 71, 81]	-0.67 to $4.62$
SF- 36 – Role Limitations Physical Subscale	3 [32, 46, 71]	3 [32, 46, 71]	0.08-4.34
SF- 36 – Role Limitations Emotional Subscale	2 [32, 46]	2 [32, 46]	-0.03 to 0.43
SF- 36 – Mental Well-Being Subscale	3 [32, 36, 46]	3 [32, 36, 46]	-2.04 to 0.89
SF- 36 – Vitality Subscale	3 [32, 45, 46]	3 [32, 45, 46]	0.63-4.39
SF- 36 – Physical Component Summary	1 [51]	1 [51]	0.16-0.54
SF- 36 – General Health Subscale	2 [32, 46]	2 [32, 46]	0.79–1.4
SF- 36 – Bodily Pain Subscale	2 [32, 46]	2 [32, 46]	-0.11 to 1.36
SF- 36 – Social Functioning Subscale	2 [32, 46]	2 [32, 46]	0.27-0.7
SF- 36 – Reported Health Transition Sub- scale	1 [46]	1 [46]	0.75
Short Form – 6D	1 [55]	1 [55]	-0.01
Functional Assessment of Chronic Illness Therapy – Fatigue Scale	8 [34, 38, 39, 51, 56, 58, 67, 75]	3 [38, 51, 67]	0.25–1.87
European Organisation for Research and Treat- ment Quality of Life (EORTC QLQC-30) – Total Score	4 [23, 26, 76, 79]	3 [23, 26, 79]	-0.05 to 2.54
EORTC QLQC-30 – Physical Functioning Subscale	6 [43, 50, 53, 60, 67, 82]	4 [43, 53, 60, 67]	0.06-1.02
EORTC QLQC-30 – Global Quality of Life Subscale	5 [43, 53, 60, 67, 80]	5 [43, 53, 60, 67, 80]	- 3.58 to 3.47
EORTC-QLQ-C30—Emotional Function Subscale	5 [43, 50, 53, 60, 82]	3 [43, 53, 60]	0.0–0.77
EORTC-QLQ-C30—Cognitive Function Subscale	5 [43, 50, 53, 60, 82]	3 [43, 53, 60]	-0.31 to 0.86
EORTC-QLQ-C30—Social Function Subscale	5 [43, 50, 53, 60, 82]	3 [43, 53, 60]	0.26-0.76
EORTC-QLQ-C30 – Role Function Sub- scale	4 [26, 50, 53, 82]	2 [26, 53]	-0.07 to 0.9
Functional Assessment of Cancer Therapy— Breast (FACT-B)	5 [44, 51, 65, 90, 91]	4 [44, 51, 65, 90]	-0.05 to 0.92
FACT-B – Physical Well-Being Subscale	3 [59, 65, 90]	2 [65, 90]	-0.22 to $-0.03$
FACT-B – Social Well-Being Subscale	1 [90]	1 [90]	0.97
FACT-B – Emotional Well-Being Subscale	1 [90]	1 [90]	0.37
FACT-B – Functional Well-Being Subscale	3 [59, 65, 90]	2 [65, 90]	-0.2 to 1.25
FACT-B4	1 [58]	0	-
Six Minute Walk Test	5 [33, 43, 52, 67, 84]	4 [33, 43, 52, 67]	0.32-0.6
Brief Pain Inventory – Pain Interference Subscale	3 [53, 64, 76]	1 [64]	-0.76 to 0.42
Activity Measure for Post-Acute Care Mobility Short Form	3 [38-40]	1 [38]	1.05
EuroQol- 5 Dimension	3 [39, 40, 79]	1 [79]	1.7
Moderate Intensity Physical Activity	3 [43, 56, 60]	3 [43, 56, 60]	-0.19 to 0.22

Journal of Cancer Survivorship

Table 3 (continued)			
Outcome tool	Number of articles including outcome tool	Number of articles with available effect sizes $(d)$	Range of effect sizes
Daily Steps	3 [41, 43, 77]	1 [43]	0.38
Seven -Day Physical Activity Recall (min/ week)	2 [67, 74]	1 [67]	0.31
Stand-up and sit-down chair test	2 [45, 46]	2 [45, 46]	0.91-1.25
Arm Lifting Test	2 [45, 46]	2 [45, 46]	-2.43 to 0.65
Trial Outcome Index	2 [65, 86]	1 [65]	-0.04
The World Health Organization Quality of Life (WHOQOL)	2 [57, 91]	0	-
QOL-BC—Social Well-Being Subscale	2 [70, 71]	1 [70]	-0.27
Functional Assessment of Cancer Therapy- Cognition (FACT-Cog) – Quality of Life Subscale	2 [47, 49]	2 [47, 49]	0.12–0.43
PEG Scale Assessing Pain Intensity and Interference	2 [39, 40]	0	-
Moderate to Vigorous Physical Activity	2 [41, 54]	1 [54]	0.39
Disabilities of the Arm, Shoulder and Hand Questionnaire	2 [58, 82]	0	-
European Organisation for Research and Treatment Quality of Life – Breast Cancer (EORTC QLQ-BR23) – Sexual Function Subscale	1 [82]	0	-
EORTC QLQ-BR23 – Sexual Enjoyment Subscale	1 [82]	0	_
Quality of Life –Breast Cancer Survivors– Physical Health Subscale	1 [64]	1 [64]	0.6
Piper Fatigue Scale-revised	1 [53]	0	-
Multidisciplinary Fatigue Inventory	1 [29]	1 [29]	0.29
Functional Assessment of Cancer Therapy – Colorectal	1 [74]	0	_
Functional Assessment of Cancer Therapy – Cervix	1 [86]	0	-
Functional Assessment of Cancer Therapy- Endocrine Subscale	1 [48]	1 [48]	0.22–1.48
Functional Assessment of Cancer Therapy – Anemia	1 [47]	1 [47]	0.08-0.22
Functional Assessment of Cancer Therapy – Prostate	1 [57]	0	-
Expanded Prostate Cancer Index Composite	1 [57]	0	-
Cantril's Ladder of Life	1 [30]	1 [30]	0.45
Functional Performance Inventory	1 [31]	0	-
Community Healthy Activities Model Program for Seniors	1 [33]	1 [33]	0.1
Sickness Impact Profile – 8	1 [23]	0	-
Symptoms Impact Profile	1 [24]	1 [24]	-0.31
AMPAC Activity Short Form	1 [38]	1 [38]	0.13
UCLA Prostate Cancer Index—Sexual Bother Subscale	1 [36]	1 [36]	0.03
UCLA Prostate Cancer Index—Urinary Incon- tinence Subscale	1 [89]	0	
Total Physical Activity	1 [65]	1 [65]	-0.07
Gait Speed	1 [66]	1 [66]	-0.27
2-Min Walk Test	1 [66]	1 [66]	0.19
30-Second Chair Stand Test	1 [66]	1 [66]	0.47

Table 3 (continued)										
Outcome tool	Number of articles including outcome tool	Number of articles with available effect sizes ( <i>d</i> )	Range of effect sizes							
International Physical Activity Questionnaire	1 [65]	1 [65]	-0.07							
Late-Life Function & Disability Instrument – Basic Lower Extremity Function Subscale	1 [72]	1 [72]	3.72							
Late-Life Function & Disability Instrument – Advanced Lower Extremity Function Subscale	1 [72]	1 [72]	3.63							
Swallowing Function: Maximum interincisal opening and Mandible Function Impairment	1 [85]	1 [85]	- 1.40 to 1.26							
Godin Leisure Time Exercise Questionnaire	1 [83]	1 [83]	2.91-4.22							
Champs Survey (Physical Activity and Life- style Behavior Subscales)	1 [37]	0	-							
PROMIS® Global Health (Physical and Men- tal Health Subscales)	1 [41]	0	-							
PROMIS® Depression Scale	1 [87]	0	-							
Short Physical Performance Battery	1 [77]	0	-							
International Index of Erectile Function Scale	1 [78]	0	-							
3-Min Step Test	1 [58]	0	-							
One Mile Walk Test	1 [73]	0	-							
Tread walk Test	1 [74]	0	-							
Sit to Stand Test	1 [43]	0	-							

#### Discussion

This systematic review assesses the current state of the science and effectiveness of telehealth-based cancer rehabilitation interventions influencing disability. Included studies were randomized controlled trials with at least one synchronous intervention delivery component and incorporated a measure of disability as a primary or exploratory outcome. Given the available data, telehealth-based cancer rehabilitation interventions appear to have a small positive effect on quality of life as measured by the FACT-G and FACIT-F measurement system, which includes an assessment of a person's perceived ability to function in daily life. The effect on physical functioning is less clear, with no effect seen when measured by the SF-36 and a small effect seen when measured by the EORTC QLQC-30. It is possible that the effects are underestimated because disability and health-related quality of life measures were not the primary outcome for the majority of the studies. In other words, a study intervention with a primary purpose to reduce a specific symptom (e.g., pain, cognitive deficits, balance) may not generalize to reductions in disability or health-related quality of life.

In sum, telehealth-based cancer rehabilitation does have an impact that merits further evaluation and study; however, the descriptive results indicate that future research will need to include more diverse patient populations, create more consensus around appropriate measure selection, and focus on implementation science methods to address challenges to translating evidence into practice.

#### Patient populations and study characteristics

Studies included in this systematic review were not evenly distributed across cancer type, timing of treatment/intervention, and location. Included studies were heavily weighted toward individuals with breast cancer (n = 30, 60%) and postprimary treatment interventions (n = 34, 50%). This is somewhat unsurprising as breast cancer is the most frequently diagnosed new cancer in women in the USA [92] and one of the most common diagnoses in more than 25 countries globally [93]. In addition, the field of cancer survivorship was initially conceptualized as beginning post-treatment completion [94]. Thus, this skew toward post-treatment intervention is consistent with the larger body of literature in cancer and rehabilitation and prevalence estimates. However, it presents three challenges. First, findings may have limited utility in determining implications for other cancer populations. Second, the implications for delivery outside the post-treatment phase also remain somewhat unclear and exposes the relatively smaller bodies of research examining effectiveness in the pre-treatment phase, during treatment, and end-of-life care. Lastly, study locations were primarily located in the USA and Northern Europe, not only limiting generalizability to many indigenous peoples and non-Western countries but also potentially reflecting lack of access to telehealth-based cancer rehabilitation services in low-income countries.

Race and ethnicity of study participants presented another area of imbalance in the included studies. Of the studies that reported ethnicity (n = 38, 56%), participants were almost

**Fig. 2** Forest plots of most commonly reported functional outcome measures with available data increase font of each section of figure

	1			-			Otom double of Ma			
tudy	Interv Total M	/ention ean S	ъτ	otal	ontrol Mean	SD	Standardised Mean Difference	SMD	95%-CI	Weight
ndorcon 2006	16 5	70 1	7.0	14	65.2	6 1	P	-0.6	[-1 2: 0 1]	4 504
nderson 2006	13 6	7.5 1	.0	14	65.2	6.1		0.0	[-0.5:1.0]	4.0%
nderson 2006	16 5	0 5 1	1.5	14	65.2	6.1		-0.5	[-0.3, 1.0]	4.270
nderson 2006	16 5	0.0 1		14	65.Z	0.1		-0.5	[-1.3, 0.2]	4.5%
sning 2016	20 5	8.2 /	.5	19	53.9	3.2		0.7	[0.1; 1.4]	5.7%
heville 2013	26	1.1 1	1.6	29	0.1	10.2		0.1	[-0.4; 0.6]	8.7%
lark 2013	65 7	4.2 13	2.6	64	68.7	13.1		0.4	[0.1;0.8]	19.9%
ates 2005	53 ´	1.2 0	.5	56	1.1	0.5	- <del> </del> #	0.2	[-0.2; 0.6]	17.1%
os Santos 2020	48 5	5.4 1	1.3	51	3.7	12.3		0.1	[-0.3; 0.5]	15.6%
os Santos 2020	44 4	4.0 1/	0.6	51	3.7	12.3		0.0	[-0.4; 0.4]	14.9%
elleher 2021	14 8	3.0 1	5.0	17	77.0	15.0		0.4	[-0.3; 1.1]	4.8%
ixed effect model eterogeneity: / <sup>2</sup> = 34%	315 $\tau^2 = 0.033$	32. p = 0.	14	329		Г		0.2	[ 0.0; 0.3]	100.0%
	,	-,,-				-2		2		
				C 1	<b>C1</b>		-avors Control Favors Interve	ention		
	M	edical O	utcom	es Study	Snort-r	orm (S	r-36) – Physical Functioning St	ubscale		
tudy	Total	Mean	SD	Total	Mean	SD	Difference	SMD	95%-CI	Weight
ennett 2007	28	47.1	11.1	28	45.5	9.8	<u></u>	0.2	[-0.4·0.7]	9.7%
hambers 2012	334	48.0	9.0	368	47.5	94	<u> </u>	0.0	[-0.1.0.2]	10.3%
	100	81 9	16.6	102	80.2	17 1	<u> </u>	0.0	[-0.2:0./1	10.3%
uijts 2012	103	01.0	16.7	103	00.2	17.1	E.	0.1	[ 0.2, 0.4]	10.270
uijts 2012	104	04.0	10.7	103	00.2	17.1	Ē	0.2	[0.0, 0.5]	10.2%
lorov 2009	210	-2.1	0.0	222	-1.9	0.0	T =	2.0	[-0.2, 0.3]	10.2%
uriele 2019	109	42.0	0.9	322	-4.0	10.9		-0.2	[2.0, 3.2]	10.2%
vijala 2010 vriele 2018	100	43.0	10.2	115	45.4	10.0	1	-0.2	[-0.4, 0.1]	10.2%
yijala 2010 popp-Engquist 2020	10	44.0	10.2 E 1	115	45.4	F 2	T	-0.7	[-0.3, 0.2]	0.40/
opd 2020	23	90.0	8.1	21	79.8	22.8		0.7	[-1.3, 0.0]	9.4%
Ū										
andom effects mode $t_{2}^{2} = 0.0\%$	→ 1264 → 1 2269	n < 0.01		1296			<u> </u>	0.3	[-0.4; 1.0]	100.0%
eterogeneity. 7 = 30%,	t = 1.2500	, p < 0.01				-	4 -2 0 2	4		
							Favors Control Favors Interve	ention		
	]	Function	al Ass	essment	t of Chro	nic Illne	ess Therapy – Fatigue Scale			
Study	Tota	Interven I Mean	ion SD	Tota	Contro I Mean	SD	Standardised Mean Difference	SMD	95%-CI \	Neight
Cheville 2013	26	4.5	8.7	29	-0.8	9.1		0.6	[ 0.0: 1.1]	23.8%
Freeman 2015	23	41.5	12.4	47	32.3	1.3		1.3	[ 0.7; 1.8]	23.7%
		39.8	8.1	47	32.3	1.3		1.3	[ 0.8; 1.7]	25.8%
Freeman 2015	48	00.0				~ ~			i a i a a	26.7%
Freeman 2015 Ligibel 2012	48 48	4.4	8.4	51	2.5	6.8		0.2	[-0.1; 0.6]	
Freeman 2015 Ligibel 2012 Random effects mo	48 48 •del 145	4.4	8.4	51 <b>174</b>	2.5	6.8		0.2 0.8	[-0.1; 0.6] [ <b>0.3; 1.4]</b> 1	100.0%
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: I <sup>2</sup> = 81 <sup>4</sup>	48 48 >del 145 %, τ <sup>2</sup> = 0.24	4.4 99, <i>p</i> < 0.	8.4 01	51 <b>174</b>	2.5	6.8		0.2	[-0.1; 0.6] [ <b>0.3; 1.4]</b> 1	100.0%
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: $I^2 = 81^{\circ}$	48 48 α <b>del 145</b> %, τ <sup>2</sup> = 0.24	4.4 99, p < 0.	8.4 01	51 <b>174</b>	2.5	6.8	-2 -1 0 1 Favors Control Favors Interve	0.2 0.8 2 ntion	[-0.1; 0.6] [ <b>0.3; 1.4]</b> 1	100.0%
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: $I^2 = 810$	48 48 <b>&gt;del 145</b> %, τ <sup>2</sup> = 0.24	4.4 99, <i>p</i> < 0.	8.4	51 174	2.5	6.8 -	-2 -1 0 1 Favors Control Favors Interve	0.2 0.8 2 ntion	[-0.1; 0.6]	100.0%
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: I <sup>2</sup> = 811 European Orga	48 48 <b>&gt;&gt;del 145</b> %, $\tau^2 = 0.24$ <b>nisation fo</b>	4.4 99, <i>p</i> < 0.	8.4 01 <b>ch and</b>	51 174 Treatr	2.5 nent Qua	6.8 - lity of I	-2 -1 0 1 Favors Control Favors Interve	0.2 0.8 2 ntion sical Fu	[-0.1; 0.6] [ 0.3; 1.4] 1 nctioning S	100.0% ubscale
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: J <sup>2</sup> = 811 European Organ	48 48 0del 145 %, $\tau^2 = 0.24$ nisation fo	4.4 99, <i>p</i> < 0. <b>r Resear</b> Interver	8.4 01 ch and tion	51 174 Treatr	2.5 nent Qua Contr	6.8 lity of I	-2 -1 0 1 Favors Control Favors Interve sife (EORTC QLQC-30) – Phy Standardised Mean	0.2 0.8 2 ntion sical Fu	[0.3; 1.4] 1	ubscale
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: / <sup>2</sup> = 819 European Organ Study	48 48 0del 145 %, $\tau^2 = 0.24$ nisation fo	4.4 99, p < 0. r Resear Interver al Mea	8.4 01 chand tion n SE	51 174 Treatr	2.5 nent Qua Contra al Mear	6.8 	-2 -1 0 1 Favors Control Favors Interve Life (EORTC QLQC-30) – Phy Standardised Mean Difference	0.2 0.8 2 ntion sical Fu SMD	[0.3; 1.4] 1 [0.3; 1.4] 1 nctioning S 95%-Cl	100.0% ubscale Weight
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: / <sup>2</sup> = 819 European Organ Study Dennett 2018	48 48 0del 145 %, $\tau^2 = 0.24$ nisation fo Tota 22	4.4 99, p < 0. r Resear Interver al Mea	8.4 01 tion n SE 17.	51 174 Treatr ) Tota 0 24	2.5 nent Qua Contr al Mear	6.8 lity of I ol 1 SD 18.0	-2 -1 0 1 Favors Control Favors Interve affe (EORTC QLQC-30) - Phy Standardised Mean Difference	0.2   0.8 2 ntion sical Fu SMD 0.1	[0.3; 1.4] 1 [0.3; 1.4] 1 nctioning S 95%-Cl [-0.5; 0.6]	ubscale Weight 22.9%
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: / <sup>2</sup> = 810 European Orgat Study Dennett 2018 Galiano-Castillo 20	48 48 odel 145 %, $\tau^2 = 0.24$ nisation fo Tota 22 16 39	4.4 99, p < 0. Interver al Meai 2 81.0 9 86.8	8.4 01 tion 1 SE 17. 12.	51 174 Treatr 0 Tota 6 37	2.5 nent Qua Contr al Mear 80.0 7 71.5	6.8 lity of I ol 18.0 17.5	-2 -1 0 1 Favors Control Favors Interve Life (EORTC QLQC-30) – Phy Standardised Mean Difference	0.2   0.8 2 ntion sical Fu SMD 0.1 1.0	[0.3; 1.4] 1 nctioning S 95%-Cl [-0.5; 0.6] [0.5; 1.5]	ubscale Weight 22.9% 27.2%
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: I <sup>2</sup> = 811 European Organ Study Dennett 2018 Galiano-Castillo 20 Hung 2014	48 48 48 <b>odel 145</b> %, $\tau^2 = 0.24$ <b>nisation fo</b> <b>Tota</b> 16 39 16	4.4 (99, p < 0. <b>r Resear</b> <b>Interver</b> <b>al Mea</b> () 81.0 () 86.8 () 34.2	8.4 01 tion 1 SE 17. 12. 20.	51 174 Treatm 0 Tota 0 24 6 37 0 17	2.5 nent Qua Contr al Mear 8 80.0 7 71.5 7 23.8	6.8 lity of I ol 18.0 17.5 23.5	-2 -1 0 1 Favors Control Favors Interve afe (EORTC QLQC-30) – Phy Standardised Mean Difference	0.2 0.8 2 ntion sical Fu SMD 0.1 1.0 0.5	[0.3; 1.4] 1 nctioning S 95%-Cl [-0.5; 0.6] [-0.2; 1.2]	100.0% ubscale Weight 22.9% 27.2% 18.7%
Freeman 2015 Ligibel 2012 Random effects mon Heterogeneity: I <sup>2</sup> = 811 European Organ Study Dennett 2018 Galiano-Castillo 201 Ligibel 2012	48 48 9 9, τ <sup>2</sup> = 0.24 nisation fo Tota 16 32 16 36 16 45	4.4 (99, p < 0. r Resear Interver al Meai 2 81.0 3 86.8 3 34.2 3 7.1	8.4 01 tion 17. 12. 20. 11.	51 174 Treatm 0 Tota 6 37 0 17 4 51	2.5 ment Qua Contra Mear 80.0 71.5 23.8 2.6	6.8 lity of L ol 18.0 17.5 23.5 10.2	-2 -1 0 1 Favors Control Favors Interve affe (EORTC QLQC-30) – Phy Standardised Mean Difference	0.2 0.8 2 ntion sical Fu 0.1 1.0 0.5 0.4	[0.3; 1.4] 1 nctioning S 95%-CI [-0.5; 0.6] [0.5; 1.5] [-0.2; 1.2] [0.0; 0.8]	ubscale Weight 22.9% 27.2% 18.7% 31.2%
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: I <sup>2</sup> = 819 European Organ Study Dennett 2018 Galiano-Castillo 201 Ligibel 2012 Random effects m	48 48 odel 145 %, τ <sup>2</sup> = 0.24 nisation fo Tot: 16 36 48 odel 12!	4.4 (199, p < 0. <b>r Resear</b> Interver al Meai 2 81.0 3 86.8 3 34.2 3 7.1 5	8.4 01 tion 1 SE 17. 12. 20. 11.	51 174 Treatr 0 Tota 0 24 6 37 0 17 4 51 129	2.5 ment Qua Contra Mear 80.0 71.5 23.8 2.6	6.8 lity of I ol 18.0 17.5 23.5 10.2	-2 -1 0 1 Favors Control Favors Interve sife (EORTC QLQC-30) – Phy Standardised Mean Difference	0.2 0.8 2 ntion sical Fu SMD 0.1 1.0 0.5 0.4 0.5	<pre>[-0.1; 0.6] [ 0.3; 1.4] 1 nctioning S 95%-Cl [-0.5; 0.6] [ 0.5; 1.5] [ -0.2; 1.2] [ 0.0; 0.8] [ 0.1; 0.9]</pre>	ubscale Weight 22.9% 27.2% 18.7% 31.2% 100.0%
Freeman 2015 Ligibel 2012 Random effects mo Heterogeneity: I <sup>2</sup> = 81 <sup>o</sup> European Organ Study Dennett 2018 Galiano–Castillo 20 Hung 2014 Ligibel 2012 Random effects m Heterogeneity: I <sup>2</sup> = 55	48 48 48 0del 145 %, $\tau^2 = 0.24$ nisation fo Tot: 116 22 116 48 0del 122 5%, $\tau^2 = 0.00$	4.4 (99, p < 0. r Resear Interver al Meai 2 81.0 3 86.8 3 34.2 3 7.1 5 B41, p = 0	8.4 01 tion 17. 12. 20. 11.	51 174 Treatr 0 Tot: 0 24 6 37 0 17 4 51 129	2.5 ment Qua Contra Mear 80.0 71.5 23.8 2.6	6.8 lity of I ol 18.0 17.5 23.5 10.2	-2 -1 0 1 Favors Control Favors Interve Life (EORTC QLQC-30) – Phy Standardised Mean Difference	0.2 0.8 2 ntion sical Fu SMD 0.1 1.0 0.5 0.4 0.5	[-0.1; 0.6] [0.3; 1.4] 1 nctioning S 95%-Cl [-0.5; 0.6] [0.5; 1.5] [-0.2; 1.2] [0.0; 0.8] [0.1; 0.9]	ubscale Weight 22.9% 27.2% 18.7% 31.2% 100.0%
Freeman 2015 Ligibel 2012 Random effects mon Heterogeneity: I <sup>2</sup> = 811 <b>European Organ</b> Study Dennett 2018 Galiano-Castillo 200 Hung 2014 Ligibel 2012 Random effects m Heterogeneity: I <sup>2</sup> = 50	48 48 0del 145 $r^2 = 0.24$ nisation fo Tot: 116 35 16 45 0del 122 5%, $r^2 = 0.03$	4.4 (99), p < 0. r Resear Interver al Meai 2 81.0 3 84.2 3 7.1 5 841, p = 0	8.4 01 tion 17. 12. 20. 11. .09	51 174 Treatr 0 Tot: 0 24 6 37 0 17 4 51 129	2.5 ment Qua Contra Mear 80.0 7.1.5 7.23.8 2.6	6.8 lity of I ol 18.0 17.5 23.5 10.2	-2 -1 0 1 Favors Control Favors Interve affe (EORTC QLQC-30) – Phy Standardised Mean Difference	0.2 0.8 2 ntion sical Fu 0.1 1.0 0.5 0.4 0.5 2	<pre>[-0.1; 0.6] [ 0.3; 1.4] 1 nctioning S 95%-Cl [-0.5; 0.6] [ 0.5; 1.5] [ -0.2; 1.2] [ 0.0; 0.8] [ 0.1; 0.9]</pre>	ubscale Weight 22.9% 27.2% 18.7% 31.2% 100.0%

exclusively White and non-Hispanic. The high number of White participants, as well as the large number of studies that did not report ethnicity (n=30, 44%), may limit the ability to generalize findings to other race and ethnicity groups. Similar to findings in this review, this has been a persistent challenge in the larger world of clinical trials [95], including in rehabilitation medicine [96]. This lack of inclusion for historically or socially marginalized groups may undermine personalized medicine efforts and contribute to the persistence of health inequities [97]. The results described in our analysis indicate that there are challenges to translation in clinical care settings beyond individuals with breast cancer and individuals outside of economically developed nations and socially marginalized populations.

There are consequences associated with ongoing lack of inclusion of historically or socially marginalized groups in cancer rehabilitation research and clinical practice. Lack of representative study samples may prevent researchers and clinicians from delivering high-quality patient-centric care [96]. Furthermore, lack of examination of social determinants of health on access, delivery, or effectiveness of telehealth-based cancer rehabilitation may perpetuate healthcare disparities and sub-optimal outcomes among vulnerable populations. Without evidence that acknowledges the influence of telehealth-based cancer rehabilitation services among marginalized groups, we are at risk of constraining the growth or applicability of the cancer rehabilitation field among the broader cancer community and inefficiently utilizing costly healthcare and research resources [96]. Thus, future research and clinical practice using telehealth-based cancer rehabilitation interventions must leverage research designs and clinical practice delivery that support inclusion of historically or socially marginalized groups.

#### **Outcomes and measurement**

When evaluating the effectiveness of interventions, one significant challenge was attributed to the number of measures utilized across the included studies. In this review, we found a wide range of patient-reported and performance-based measures of disability, specifically, 55 different measures (or 84 if you consider the sub-scales of larger patient-reported outcome measures). Similar to previous studies [98, 99], this has led to difficulty in determining outcome magnitude and direction across this body of research [100]. Furthermore, the measures most frequently used in this study are typically free for research, but may not be financially feasible in clinical practice [101]. This places additional financial burden on clinics that who have to pay per patient to use the measure as well as cover costly and time-consuming data entry solutions.

For research and systematic reviews to inform clinical practice, guidelines, and policy, the outcomes chosen need to be prioritized in terms of meaningfulness to the patients served. Second, the outcomes chosen in clinical research should be standardized to decrease potential bias, poor selection of measures with lacking psychometrics, or gathering data that may not be relevant across studies which prevent further synthesis and knowledge gained. It is challenging to integrate this research directly into clinical practice as well as for the clinical practice to be prepared to gather relevant data. There is some recent work that seeks to harmonize outcome measures to place multiple measures onto one metric and, therefore, allow meta-analysis or comparative effectiveness research to occur [102]. Until harmonization efforts are underway, standardized, and easy to use and understand in a busy clinical practice, in clinic- or telehealth-based cancer rehabilitation, we strongly encourage a consensus and collaboration to determine measures that have clinical utility and research utility.

## Intervention development and intervention considerations

#### Technology and patient preferences

The significant role of "old" or "low-tech" technology of the telephone (n = 40, 59%) stands out in contrast to rapid upscaling of video technology during the COVID-19 pandemic. Although our inclusion of articles spanned through April 2021, our dataset contained only 11 articles published

in 2020 or 2021 and most of them were accepted for publication prior to March 2020. It is likely that our inclusion criterion regarding the use of an RCT design limited our ability to capture and describe studies that incorporated video technology and newer telehealth platforms that were introduced in the COVID-19 pandemic era.

During the COVID-19 pandemic, less restrictive use of telehealth has been permitted within the USA [103], including reimbursement for services provided by telephone. Globally, utilization of telehealth-based services tended to use different types of telehealth services based on the health condition or severity of complaint [104]. Nevertheless, if telehealth-based cancer rehabilitation via telephone delivery is deemed a non-reimbursed service post-pandemic, it limits use of an easily accessible mode of delivery. There is little research comparing patient preferences for phone versus other telehealth delivery methods; however, three recent studies [105–107] in oncology supportive services and medical consultation have examined patient preferences and satisfaction. These studies found that a plurality of patients preferred telephone delivered care over face-toface and/or video delivered care. Interestingly, one study in Canada found comprehensive functional assessments could also be delivered primarily via telephone and supplemented with one or two in-person visits [107]. Qualitative methods examining patient preferences and satisfaction with telehealth-based cancer rehabilitation services can help shape modes of delivery in future and existing interventions across global healthcare systems.

#### **Professional disciplines**

In our results, over one-third (n = 24, 35%) of study interventions were delivered by nursing professionals. Our classification of nursing professionals included nursing assistants, nurses, and nurse practitioners. The billing implications of this finding are unclear given the wide range of legal independent practice ability and billing requirements within this category. Moreover, varying scope of practice issues (i.e., implementing an intervention versus setting and advancing the plan of care) between rehabilitation clinicians also render this finding challenging to interpret and implement. Given the breadth of interventionists and missing data, we were unable to identify if differences in discipline delivery influenced improvement in disability. Future research can elucidate differences in outcomes based on discipline.

#### Intervention characteristics

Interventions varied in duration and time and format of delivery. The mean intervention duration was 16.5 weeks. In conjunction with our findings, most studies were delivered post-treatment. In addition, interventions varied in intensity and format (i.e., one-on-one services to group therapy). Therefore, it may be possible that intervention intensity also impacts duration. Moreover, real-world application of these findings may not be feasible in regional and/or global clinical settings. For example, the duration may not accurately reflect the shorter timetables necessary for telehealth-based cancer rehabilitation interventions prior to initiating primary treatment or in the context of advanced disease or end of life.

#### Limitations

To our knowledge, this is the first systematic review to broadly address the effectiveness of telehealth-based cancer rehabilitation in cancer survivors. Given this, we chose a wide lens through which to select eligible studies to provide the broadest perspective on randomized controlled trials in this area of practice. That said, there are limitations. First, inclusion of only randomized controlled trials may have led us focus on efficacy trials in academic settings and miss pragmatic trials in clinical settings, including those stimulated by the COVID-19 pandemic. Although there were eleven articles published between 2020 and 2021 [32, 37, 41, 46, 50, 62, 71, 76, 80, 84, 90], no articles took place during or referenced the COVID-19 pandemic. Future research should consider differences among pre-, during-, and postpandemic telehealth-based cancer rehabilitation intervention research in terms of populations reached, functional measures used and associated outcomes, as well as technology platforms utilized. This information could be used to influence health system access and broader policy related to telehealth reimbursement and utilization.

Second, creating an operational definition of cancer rehabilitation was a challenge that introduced heterogeneity into the sample. As such, our review is broad and expansive and may include interventions that the authors may not have identified as rehabilitation. Co-authors also represented a broad range of professional disciplines and expertise to capture all interventions that may be considered as cancer rehabilitation.

For this study, we chose not to analyze active ingredients or components of the included interventions as our primary focus was to characterize delivery and evaluate the effect on disability. Future work will identify and examine which active ingredients or intervention content influence function and disability via telehealth-based services the most. Following this, future research may also consider stakeholder input on preferred or prioritized types of intervention to be delivered via telehealth to ensure value of future intervention.

We chose to include studies with some concerns and high risk of bias in order to comprehensively characterize the state of the science in this area. Thus, inclusion of this evidence helps to broaden our understanding of potential implications for future intervention development, implementation, and policy applications. However, given the large amount of missing data (i.e., raw means and standard deviations) and moderate to high risk of bias associated with many included studies, the certainty, or the test of accuracy, of our findings may have been impacted. The variation in interventions and outcome measures included in this systematic review preclude meta-analysis. No inquiries were made to the authors of the original articles for clarification or missing data which could affect the validity of the effectiveness analysis. While our analyses indicated small positive effects on disability, heterogeneity across population and intervention characteristics prevent us from drawing firm conclusions.

### Conclusion

To summarize, in the rapidly changing context of science, practice, and policy, telehealth-based cancer rehabilitation demonstrates a positive impact that merits further evaluation and study. Based on the results of this review, telehealthbased cancer rehabilitation interventions show promise to improve disability for cancer patients. In light of the cited limitations, how should the field move forward? Widening the patient populations studied building the evidence base for interventions prior to primary cancer treatment, and across multiple stages of the cancer trajectory, including end of life are necessary. Patient preferences, satisfaction, and outcomes with all telehealth modalities including low-tech options such as telephones should be explored. In addition, determining which therapies are most efficacious in telehealth modalities and which patients will benefit from specific therapies is of utmost importance. Consensus around appropriate measures is needed to be able to build the body of evidence. Lastly, assessing feasibility and translation potential must be addressed via implementation science methods. It is essential to conduct pragmatic trials, in order to know how to best meet the needs of cancer survivors. For future intervention research, it will be imperative to recruit and involve representative study samples related to race/ethnicity, socioeconomic status, and technology literacy to enhance generalizability of study findings to real-world settings. The questions are there; it is our mission to build the evidence.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11764-022-01181-4.

Acknowledgements The authors would like to acknowledge the members of the Outcomes and Research Task Force of the Cancer Rehabilitation Networking Group of the American Congress of Rehabilitation Medicine for their support of this work. Portions of these data were presented at the 2021 American Congress of Rehabilitation Medicine Virtual Conference on September 28, 2021 in a symposia presentation.

Author contribution The following authors contributed to study conception and design: RB, KDL, JJ, LP, KCW, MP, TM, GC, JKS, AV, AL, TK. The following authors contributed to data screening: RB, KDL, JJ, LP, KCW, MP, TM, GC, RE, JKS, AV, AMF, MF, RK, JB, TK. The following authors contributed to data extraction: RB, KDL, JJ, LP, KCW, MP, TM, GC, RE, JS, AV, AMF, MF, TK, JB, RE. The following authors contributed to data analysis and interpretation: RB, KDL, MP, LP, JJ, JB, AB, GB, SK. All authors contributed to manuscript writing and approval.

**Funding** Dr. Flores reports funding from the National Cancer Institute (3UM1CA233035-01S1).

**Data availability** The de-identified transcriptions and dataset analyzed in the current study are available upon request to the corresponding author.

#### Declarations

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

**Conflict of interest** Drs. Pergolotti and Covington, and Tiffany Kendig report personal fees from Select Medical, ReVital Cancer Rehab outside the submitted work. Julie K. Silver has participated in research funded by the Binational Scientific Foundation and is a venture partner for Third Culture Capital outside of the work submitted. Aneesha Virani receives salary for full-time employment at Northside Hospital for work outside of submitted work. Aneesha Virani reports participating in research funded by the American Speech & Hearing Foundation for work outside of this project. Grace Campbell reports funding from the National Institute of Disability, Independent Living, and Rehabilitation Research. Kathleen D. Lyons reports participating in research funded by the National Cancer Institute for work outside of this project. All other authors declare no competing interests.

#### References

- O'Young B, Gosney J, Ahn C. The concept and epidemiology of disability. Phys Med Rehabil Clin N Am. 2019;30(4):697–707. https://doi.org/10.1016/j.pmr.2019.07.012.
- Neo J, Fettes L, Gao W, Higginson IJ, Maddocks M. Disability in activities of daily living among adults with cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2017;61(Supplement C):94–106. https://doi.org/10.1016/j.ctrv.2017.10.006.
- Alfano CM, Kent EE, Padgett LS, Grimes M, de Moor JS. Making cancer rehabilitation services work for cancer patients: recommendations for research and practice to improve employment outcomes. PM R. 2017;9(9, Supplement 2):S398–406. https:// doi.org/10.1016/j.pmrj.2017.06.019.
- Starmer HM. Factors influencing adherence to treatment for head and neck cancer. In: Doyle PC, editor. Clinical care and rehabilitation in head and neck cancer. Cham: Springer International Publishing; 2019. p. 413–22. https://doi.org/10.1007/978-3-030-04702-3\_24.

- Chasen MR. Cancer nutrition and rehabilitation its time has come! Curr Oncol. 2008;15(3):6. https://doi.org/10.3747/co. v15i3.244.
- Cheville AL, Morrow M, Smith SR, Basford JR. Integrating function-directed treatments into palliative care. PM R. 2017;9(9, Supplement 2):S335–46. https://doi.org/10.1016/j.pmrj.2017.07. 073.
- Khan F, Amatya B, Ng L, Demetrios M, Zhang NY, Turner-Stokes L. Multidisciplinary rehabilitation for follow-up of women treated for breast cancer. Cochrane Database Syst Rev. 2012;12:CD009553. https://doi.org/10.1002/14651858.CD009 553.pub2.
- Khan F, Amatya B, Ng L, Drummond K, Galea M. Multidisciplinary rehabilitation after primary brain tumour treatment. Cochrane Database Syst Rev. 2015;8:CD009509. https://doi. org/10.1002/14651858.CD009509.pub3.
- Scott DA, Mills M, Black A, et al. Multidimensional rehabilitation programmes for adult cancer survivors. Cochrane Database Syst Rev. 2013;3:CD007730. https://doi.org/10.1002/14651858. CD007730.pub2.
- Mewes JC, Steuten LMG, IJzerman MJ, van Harten WH. Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review. Oncologist. 2012;17(12):1581–93. https://doi.org/ 10.1634/theoncologist.2012-0151.
- Pergolotti M, Deal AM, Lavery J, Reeve BB, Muss HB. The prevalence of potentially modifiable functional deficits and the subsequent use of occupational and physical therapy by older adults with cancer. J Geriatr Oncol. 2015;6(3):194–201. https:// doi.org/10.1016/j.jgo.2015.01.004.
- Cheville AL, Kornblith AB, Basford JR. An examination of the causes for the underutilization of rehabilitation services among people with advanced cancer. Am J Phys Med Rehabil. 2011;90(5 Suppl 1):S27-37. https://doi.org/10.1097/PHM.0b013 e31820be3be.
- Stubblefield MD. The underutilization of rehabilitation to treat physical impairments in breast cancer survivors. PM R. 2017;9(9, Supplement 2):S317–23. https://doi.org/10.1016/j.pmrj.2017.05. 010.
- Cheville AL, Mustian K, Winters-Stone K, Zucker DS, Gamble GL, Alfano CM. Cancer rehabilitation: an overview of current need, delivery models, and levels of care. Phys Med Rehabil Clin N Am. 2017;28(1):1–17. https://doi.org/10.1016/j.pmr.2016.08. 001.
- Cheville AL, Rhudy L, Basford JR, Griffin JM, Flores AM. How receptive are patients with late stage cancer to rehabilitation services and what are the sources of their resistance? Arch Phys Med Rehabil. 2017;98(2):203–10. https://doi.org/10.1016/j.apmr. 2016.08.459.
- Alfano CM, Leach CR, Smith TG, et al. Equitably improving outcomes for cancer survivors and supporting caregivers: a blueprint for care delivery, research, education, and policy. CA Cancer J Clin. 2019;69(1):35–49. https://doi.org/10.3322/caac.21548.
- World Health Organization. Telemedicine: Opportunities and developments in member states. Global Observatory for eHealth series - Volume 2. Geneva, Switzerland. 2010. Accessed 6 Dec 2021. https://www.who.int/goe/publications/goe\_telemedicine\_ 2010.pdf.
- Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https://doi.org/10.1186/ 2046-4053-4-1.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71.

- Higgins JP, Sterne JA, Savovic J, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane Methods. Cochrane Database of Systematic Reviews. 2016; 10: p. 29–31. https://doi.org/10.1002/14651858.CD201601.
- Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006;59(11):990–6. https://doi.org/10.1016/j.biopsych.2005. 09.014.
- Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. https://doi.org/ 10.1002/sim.1186.
- 23. Abrahams HJG, Gielissen MFM, Donders RRT, et al. The efficacy of internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: a randomized controlled trial. Cancer. 2017;123(19):3825–34. https://doi.org/10.1002/cncr.30815.
- 24. Allard NC. Day surgery for breast cancer: effects of a psychoeducational telephone intervention on functional status and emotional distress. Oncol Nurs Forum. 2007;34(1):133–41. https://doi.org/10.1188/07.ONF.133-141.
- Anderson KO, Cohen MZ, Mendoza TR, Guo H, Harle MT, Cleeland CS. Brief cognitive-behavioral audiotape interventions for cancer-related pain: immediate but not long-term effectiveness. Cancer. 2006;107(1):207–14. https://doi.org/ 10.1002/cncr.21964.
- 26. Aranda S, Schofield P, Weih L, Milne D, Yates P, Faulkner R. Meeting the support and information needs of women with advanced breast cancer: a randomised controlled trial. Br J Cancer. 2006;95(6):667–73. https://doi.org/10.1038/sj.bjc. 6603320.
- Ashing KT, Miller AM. Assessing the utility of a telephonically delivered psychoeducational intervention to improve healthrelated quality of life in African American breast cancer survivors: a pilot trial. Psychooncology. 2016;25(2):236–8. https:// doi.org/10.1002/pon.3823.
- Ashing-Giwa KT. Enhancing physical well-being and overall quality of life among underserved Latina-American cervical cancer survivors: feasibility study. J Cancer Surviv. 2008;2(3):215– 23. https://doi.org/10.1007/s11764-008-0061-2.
- Badger TA, Segrin C, Hepworth JT, Pasvogel A, Weihs K, Lopez AM. Telephone-delivered health education and interpersonal counseling improve quality of life for Latinas with breast cancer and their supportive partners. Psychooncology. 2013;22(5):1035–42. https://doi.org/10.1002/pon.3101.
- 30. Bailey DE Jr, Mishel MH, Belyea M, Stewart JL, Mohler J. Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs. 2004;27(5):339–46. https://doi.org/10.1097/00002 820-200409000-00001.
- Barsevick AM, Dudley W, Beck S, Sweeney C, Whitmer K, Nail L. A randomized clinical trial of energy conservation for patients with cancer-related fatigue. Cancer. 2004;100(6):1302–10. https://doi.org/10.1002/cncr.20111.
- 32. Basen-Engquist KM, Raber M, Carmack CL, et al. Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: a randomized controlled pilot study. Support Care Cancer. 2020;28(12):5821–32. https://doi.org/10.1007/s00520-020-05411-2.
- Bennett JA, Lyons KS, Winters-Stone K, Nail LM, Scherer J. Motivational interviewing to increase physical activity in longterm cancer survivors: a randomized controlled trial. Nurs Res. 2007;56(1):18–27. https://doi.org/10.1097/00006199-20070 1000-00003.
- 34. Bruera E, Yennurajalingam S, Palmer JL, et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase

II trial. J Clin Oncol. 2013;31(19):2421–7. https://doi.org/10. 1200/JCO.2012.45.3696.

- Burns CL, Kularatna S, Ward EC, Hill AJ, Byrnes J, Kenny LM. Cost analysis of a speech pathology synchronous telepractice service for patients with head and neck cancer. Head Neck. 2017;39(12):2470–80. https://doi.org/10.1002/hed.24916.
- Chambers SK, Ferguson M, Gardiner RA, Aitken J, Occhipinti S. Intervening to improve psychological outcomes for men with prostate cancer. Psychooncology. 2013;22(5):1025–34. https:// doi.org/10.1002/pon.3095.
- 37. Chan JM, Van Blarigan EL, Langlais CS, et al. Feasibility and acceptability of a remotely delivered, web-based behavioral intervention for men with prostate cancer: four-arm randomized controlled pilot trial. J Med Internet Res. 2020;22(12): e19238. https://doi.org/10.2196/19238.
- Cheville AL, Kollasch J, Vandenberg J, et al. A home-based exercise program to improve function, fatigue, and sleep quality in patients with stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manag. 2013;45(5):811–21. https://doi.org/10.1016/j.jpainsymman.2012.05.006.
- Cheville AL, Moynihan T, Basford JR, et al. The rationale, design, and methods of a randomized, controlled trial to evaluate the effectiveness of collaborative telecare in preserving function among patients with late stage cancer and hematologic conditions. Contemp Clin Trials. 2018;64:254–64. https://doi.org/10. 1016/j.cct.2017.08.021.
- Cheville AL, Moynihan T, Herrin J, Loprinzi C, Kroenke K. Effect of collaborative telerehabilitation on functional impairment and pain among patients with advanced-stage cancer: a randomized clinical trial. JAMA Oncol. 2019;5(5):644–52. https://doi.org/10.1001/jamaoncol.2019.0011.
- Chow EJ, Doody DR, Di C, et al. Feasibility of a behavioral intervention using mobile health applications to reduce cardiovascular risk factors in cancer survivors: a pilot randomized controlled trial. J Cancer Surviv. 2020. https://doi.org/10.1007/ s11764-020-00949-w.
- Clark MM, Rummans TA, Atherton PJ, et al. Randomized controlled trial of maintaining quality of life during radiotherapy for advanced cancer. Cancer. 2013;119(4):880–7. https://doi.org/10. 1002/cncr.27776.
- Dennett AM, Shields N, Peiris CL, et al. Motivational interviewing added to oncology rehabilitation did not improve moderateintensity physical activity in cancer survivors: a randomised trial. J Physiother. 2018;64(4):255–63. https://doi.org/10.1016/j.jphys. 2018.08.003.
- Djuric Z, Ellsworth JS, Weldon AL, et al. A diet and exercise intervention during chemotherapy for breast cancer. Open Obes J. 2011;3:87–97. https://doi.org/10.2174/1876823701103010087.
- 45. Dong X, Yi X, Gao D, et al. The effects of the combined exercise intervention based on internet and social media software (CEI-BISMS) on quality of life, muscle strength and cardiorespiratory capacity in Chinese postoperative breast cancer patients: a randomized controlled trial. Health Qual Life Outcomes. 2019;17(1):109. https://doi.org/10.1186/s12955-019-1183-0.
- 46. Dong X, Yi X, Ding M, et al. A longitudinal study of a multicomponent exercise intervention with remote guidance among breast cancer patients. Int J Environ Res Public Health. 2020;17(10). https://doi.org/10.3390/ijerph17103425.
- Dos Santos M, Hardy-Léger I, Rigal O, et al. Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: a 3-arm randomized trial. Cancer. 2020;126(24):5328–36. https://doi.org/10.1002/cncr.33186.
- 48. Duijts SF, van Beurden M, Oldenburg HS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J

Clin Oncol. 2012;30(33):4124–33. https://doi.org/10.1200/JCO. 2012.41.8525.

- Ferguson RJ, Sigmon ST, Pritchard AJ, et al. A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer. 2016;122(11):1782–91. https://doi.org/10.1002/ cncr.29891.
- Fjell M, Langius-Eklöf A, Nilsson M, Wengström Y, Sundberg K. Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer - a randomized controlled trial. Breast. 2020;51:85–93. https://doi.org/ 10.1016/j.breast.2020.03.004.
- 51. Freeman LW, White R, Ratcliff CG, et al. A randomized trial comparing live and telemedicine deliveries of an imagerybased behavioral intervention for breast cancer survivors: reducing symptoms and barriers to care. Psychooncology. 2015;24(8):910–8. https://doi.org/10.1002/pon.3656.
- 52. Galiano-Castillo N, Arroyo-Morales M, Lozano-Lozano M, et al. Effect of an internet-based telehealth system on functional capacity and cognition in breast cancer survivors: a secondary analysis of a randomized controlled trial. Support Care Cancer. 2017;25(11):3551–9. https://doi.org/10.1007/ s00520-017-3782-9.
- 53. Galiano-Castillo N, Cantarero-Villanueva I, Fernandez-Lao C, et al. Telehealth system: a randomized controlled trial evaluating the impact of an internet-based exercise intervention on quality of life, pain, muscle strength, and fatigue in breast cancer survivors. Cancer. 2016;122(20):3166–74. https://doi.org/10.1002/ cncr.30172.
- Gell NM, Grover KW, Savard L, Dittus K. Outcomes of a text message, Fitbit, and coaching intervention on physical activity maintenance among cancer survivors: a randomized control pilot trial. J Cancer Surviv. 2019. https://doi.org/10.1007/ s11764-019-00831-4.
- 55. Gordon LG, Patrao T, Kularatna S, Hawkes AL. A telephonedelivered multiple health behaviour change intervention for colorectal cancer survivors: making the case for cost-effective healthcare. Eur J Cancer Care. 2015;24(6):854–61. https://doi. org/10.1111/ecc.12345.
- Hawkes AL, Chambers SK, Pakenham KI, et al. Effects of a telephone-delivered multiple health behavior change intervention (CanChange) on health and behavioral outcomes in survivors of colorectal cancer: a randomized controlled trial. J Clin Oncol. 2013;31(18):2313–21. https://doi.org/10.1200/JCO.2012.45. 5873.
- 57. Hawkins RP, Pingree S, Van Bogaert D, et al. The impact of combining human and online supportive resources for prostate cancer patients. J Commun Support Oncol. 2017;15(6):e321-e9. https://doi.org/10.12788/jcso.0330.
- Hayes SC, Rye S, Disipio T, et al. Exercise for health: A randomized, controlled trial evaluating the impact of a pragmatic, translational exercise intervention on the quality of life, function and treatment-related side effects following breast cancer. Breast Cancer Res Treat. 2013;137(1):175–86. https://doi.org/10.1007/ s10549-012-2331-y.
- Hegel MT, Lyons KD, Hull JG, et al. Feasibility study of a randomized controlled trial of a telephone-delivered problemsolving-occupational therapy intervention to reduce participation restrictions in rural breast cancer survivors undergoing chemotherapy. Psychooncology. 2011;20(10):1092–101. https://doi.org/ 10.1002/pon.1830.
- Hung YC, Bauer JD, Horsely P, Coll J, Bashford J, Isenring EA. Telephone-delivered nutrition and exercise counselling after auto-SCT: a pilot, randomised controlled trial. Bone Marrow Transplant. 2014;49(6):786–92. https://doi.org/10.1038/bmt. 2014.52.

- Jensen BT, Kristensen SA, Christensen SV, Borre M. Efficacy of tele-nursing consultations in rehabilitation after radical prostatectomy: a randomised controlled trial study. Int J Urol Nurs. 2011;5(3):123–30. https://doi.org/10.1111/j.1749-771X.2011. 01130.x.
- 62. Kelleher SA, Fisher HM, Winger JG, et al. Feasibility, engagement, and acceptability of a behavioral pain management intervention for colorectal cancer survivors with pain and psychological distress: data from a pilot randomized controlled trial. Support Care Cancer. 2021. https://doi.org/10.1007/s00520-021-06126-8.
- 63. Kim SH, Choe YH, Han AR, et al. Design of a randomized controlled trial of a partnership-based, needs-tailored self-management support intervention for post-treatment breast cancer survivors. BMC Cancer. 2020;20(1):367. https://doi.org/10.1186/ s12885-020-06861-x.
- Koller A, Gaertner J, De Geest S, Hasemann M, Becker G. Testing the implementation of a pain self-management support intervention for oncology patients in clinical practice: a randomized controlled pilot study (ANtiPain). Cancer Nurs. 2018;41(5):367– 78. https://doi.org/10.1097/ncc.00000000000502.
- Lahart IM, Metsios GS, Nevill AM, Kitas GD, Carmichael AR. Randomised controlled trial of a home-based physical activity intervention in breast cancer survivors. BMC Cancer. 2016;16(1). https://doi.org/10.1186/s12885-016-2258-5.
- 66. Lee BJ, Park YH, Lee JY, Kim SJ, Jang Y, Lee JI. Smartphone application versus pedometer to promote physical activity in prostate cancer patients. Telemed J E Health. 2019;25(12):1231– 6. https://doi.org/10.1089/tmj.2018.0233.
- Ligibel JA, Meyerhardt J, Pierce JP, et al. Impact of a telephonebased physical activity intervention upon exercise behaviors and fitness in cancer survivors enrolled in a cooperative group setting. Breast Cancer Res Treat. 2012;132(1):205–13. https://doi. org/10.1007/s10549-011-1882-7.
- Meneses K, Pisu M, Azuero A, Benz R, Su X, McNees P. A telephone-based education and support intervention for rural breast cancer survivors: a randomized controlled trial comparing two implementation strategies in rural Florida. J Cancer Surviv. 2020;14(4):494–503. https://doi.org/10.1007/ s11764-020-00866-y.
- Meneses K, Gisiger-Camata S, Benz R, et al. Telehealth intervention for Latina breast cancer survivors: a pilot. Womens Health (Lond). 2018;14:1745506518778721. https://doi.org/10.1177/ 1745506518778721.
- Meneses K, McNees P, Azuero A, Loerzel VW, Su X, Hassey LA. Preliminary evaluation of psychoeducational support interventions on quality of life in rural breast cancer survivors after primary treatment. Cancer Nurs. 2009;32(5):385–97. https://doi. org/10.1097/NCC.0b013e3181a850e6.
- Meneses KD, McNees P, Loerzel VW, Su X, Zhang Y, Hassey LA. Transition from treatment to survivorship: effects of a psychoeducational intervention on quality of life in breast cancer survivors. Oncol Nurs Forum. 2007;34(5):1007–16. https://doi. org/10.1188/07.Onf.1007-1016.
- Morey MC, Snyder DC, Sloane R, et al. Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. JAMA. 2009;301(18):1883–91. https://doi.org/ 10.1001/jama.2009.643.
- Pinto BM, Frierson GM, Rabin C, Trunzo JJ, Marcus BH. Homebased physical activity intervention for breast cancer patients. J Clin Oncol. 2005;23(15):3577–87. https://doi.org/10.1200/JCO. 2005.03.080.
- Pinto BM, Papandonatos GD, Goldstein MG. A randomized trial to promote physical activity among breast cancer patients. Health Psychol. 2013;32(6):616–26. https://doi.org/10.1037/a0029886.

- Pinto BM, Papandonatos GD, Goldstein MG, Marcus BH, Farrell N. Home-based physical activity intervention for colorectal cancer survivors. Psychooncology. 2013;22(1):54–64. https://doi. org/10.1002/pon.2047.
- Raphaelis S, Frommlet F, Mayer H, Koller A. Implementation of a nurse-led self-management support intervention for patients with cancer-related pain: a cluster randomized phase-iv study with a stepped wedge design (EvANtiPain). BMC Cancer. 2020;20(1):559. https://doi.org/10.1186/s12885-020-06729-0.
- 77. Sajid S, Dale W, Mustian K, et al. Novel physical activity interventions for older patients with prostate cancer on hormone therapy: a pilot randomized study. J Geriatr Oncol. 2016;7(2):71–80. https://doi.org/10.1016/j.jgo.2016.02.002.
- Scura KW, Budin W, Garfing E. Telephone social support and education for adaptation to prostate cancer: a pilot study. Oncol Nurs Forum. 2004;31(2):335–8. https://doi.org/10.1188/04.Onf. 335-338.
- Silvers MA, Savva J, Huggins CE, Truby H, Haines T. Potential benefits of early nutritional intervention in adults with upper gastrointestinal cancer: a pilot randomised trial. Support Care Cancer. 2014;22(11):3035–44. https://doi.org/10.1007/ s00520-014-2311-3.
- Sui Y, Wang T, Wang X. The impact of WeChat app-based education and rehabilitation program on anxiety, depression, quality of life, loss of follow-up and survival in non-small cell lung cancer patients who underwent surgical resection. Eur J Oncol Nurs. 2020;45: 101707. https://doi.org/10.1016/j.ejon.2019.101707.
- Syrjala KL, Yi JC, Artherholt SB, et al. An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation. J Cancer Surviv. 2018;12(4):560–70. https://doi.org/10. 1007/s11764-018-0693-9.
- Temur K, Kapucu S. The effectiveness of lymphedema self-management in the prevention of breast cancer-related lymphedema and quality of life: a randomized controlled trial. Eur J Oncol Nurs. 2019;40:22–35. https://doi.org/10.1016/j.ejon.2019.02. 006.
- Vallerand JR, Rhodes RE, Walker GJ, Courneya KS. Feasibility and preliminary efficacy of an exercise telephone counseling intervention for hematologic cancer survivors: a phase II randomized controlled trial. J Cancer Surviv. 2018;12(3):357–70. https://doi.org/10.1007/s11764-018-0675-y.
- Waller E, Sutton P, Rahman S, Allen J, Saxton J, Aziz O. Prehabilitation with wearables versus standard of care before major abdominal cancer surgery: a randomised controlled pilot study (trial registration: NCT04047524). 2021. Surg Endosc. https:// doi.org/10.1007/s00464-021-08365-6.
- Wang TJ, Su JH, Leung KW, Liang SY, Wu SF, Wang HM. Effects of a mouth-opening intervention with remote support on adherence, the maximum interincisal opening, and mandibular function of postoperative oral cancer patients: a randomized clinical trial. Eur J Oncol Nurs. 2019;40:111–9. https://doi.org/ 10.1016/j.ejon.2019.04.001.
- Wenzel L, Osann K, Hsieh S, Tucker JA, Monk BJ, Nelson EL. Psychosocial telephone counseling for survivors of cervical cancer: results of a randomized biobehavioral trial. J Clin Oncol. 2015;33(10):1171–9. https://doi.org/10.1200/jco.2014.57.4079.
- Yanez B, McGinty HL, Mohr DC, et al. Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer. Cancer. 2015;121(24):4407–15. https://doi.org/10.1002/cncr. 29658.
- 88. Yates P, Aranda S, Margraves M, et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast

cancer. J Clin Oncol. 2005;23(25):6027–36. https://doi.org/10. 1200/JCO.2005.01.271.

- Zhang AY, Bodner DR, Fu AZ, et al. Effects of patient centered interventions on persistent urinary incontinence after prostate cancer treatment: a randomized, controlled trial. J Urol. 2015;194(6):1675–81. https://doi.org/10.1016/j.juro.2015.07.090.
- Zhou K, Wang W, Zhao W, et al. Benefits of a WeChat-based multimodal nursing program on early rehabilitation in postoperative women with breast cancer: a clinical randomized controlled trial. Int J Nurs Stud. 2020;106: 103565. https://doi.org/ 10.1016/j.ijnurstu.2020.103565.
- 91. Kim SC, Hawkins RP, Shah DV, Gustafson DH, Baker TB. Understanding how e-health interventions meet psychosocial needs of breast cancer patients: the pathways of influence on quality of life and cancer concerns. Psychooncology. 2020;29(10):1704–12. https://doi.org/10.1002/pon.5512.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10. 3322/caac.21654.
- Ahmad A. Breast cancer statistics: Recent trends. In: Ahmad A, editor. Breast cancer metastasis and drug resistance: challenges and progress. Cham: Springer International Publishing; 2019. p. 1–7.
- Stout NL, Alfano CM, Belter CW, et al. A bibliometric analysis of the landscape of cancer rehabilitation research (1992–2016). J Natl Cancer Inst. 2018;110(8):815–24. https://doi.org/10.1093/ jnci/djy108.
- Petkovic J, Jull J, Yoganathan M, et al. Reporting of health equity considerations in cluster and individually randomized trials. Trials. 2020;21(1):308. https://doi.org/10.1186/s13063-020-4223-5.
- 96. Silver JK, Flores LE, Mondriguez Gonzalez A, Frontera WR. An analysis of the inclusion of women, older individuals, and racial/ ethnic minorities in rehabilitation clinical trials. Am J Phys Med Rehabil. 2021;100(6):546–54. https://doi.org/10.1097/PHM. 000000000001750.
- 97. Saini G, Gogineni K, Kittles RA, Aneja R. Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials. Breast Cancer Res Treat. 2021;187(3):605–11. https://doi.org/10.1007/ s10549-021-06264-x.
- Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13(1):132. https://doi.org/10.1186/1745-6215-13-132.
- Macefield RC, Jacobs M, Korfage IJ, et al. Developing core outcomes sets: methods for identifying and including patientreported outcomes (PROS). Trials. 2014;15(1):49. https://doi. org/10.1186/1745-6215-15-49.
- Ribeiro IL, Moreira RFC, Ferrari AV, Alburquerque-Sendín F, Camargo PR, Salvini TF. Effectiveness of early rehabilitation on range of motion, muscle strength and arm function after breast cancer surgery: a systematic review of randomized controlled trials. Clin Rehabil. 2019;33(12):1876–86. https://doi.org/10.1177/ 0269215519873026.
- 101. Ramsey I, Eckert M, Hutchinson AD, Marker J, Corsini N. Core outcome sets in cancer and their approaches to identifying and selecting patient-reported outcome measures: a systematic review. J Patient-Report Outcomes. 2020;4(1):77. https://doi.org/ 10.1186/s41687-020-00244-3.
- Choi SW, Schalet B, Cook KF, Cella D. Establishing a common metric for depressive symptoms: linking the BDI-II, CES-D, and PHQ-9 to PROMIS depression. Psychol Assess. 2014;26(2):513– 27. https://doi.org/10.1037/a0035768.
- 103. Fiani B, Siddiqi I, Lee SC, Dhillon L. Telerehabilitation: development, application, and need for increased usage in

the COVID-19 era for patients with spinal pathology. Cureus. 2020;12(9):e10563-e. https://doi.org/10.7759/cureus.10563.

- 104. Winburn AS, Brixey JJ, Langabeer J, Champagne-Langabeer T. A systematic review of prehospital telehealth utilization. J Telemed Telecare. 2017;24(7):473–81. https://doi.org/10.1177/ 1357633X17713140.
- 105. Myers Virtue S, Howrey HL, Duffy NM, Wallace M. Shifting psychosocial oncology care to telepsychology during the COVID-19 pandemic. J Psychosoc Oncol. 2021;39(3):416–27. https://doi.org/10.1080/07347332.2021.1894526.
- 106. Stewart R, Collins L, Kerr B, et al. A review of telephone consultations for head and neck cancer follow up: a patient satisfaction survey. J Laryngol Otol. 2021;135(9):815–9. https://doi.org/10. 1017/S0022215121001997.

#### **Authors and Affiliations**

107. Lopez CJ, Edwards B, Langelier DM, Chang EK, Chafranskaia A, Jones JM. Delivering virtual cancer rehabilitation programming during the first 90 days of the COVID-19 pandemic: a multimethod study. Arch Phys Med Rehabil. 2021;102(7):1283–93. https://doi.org/10.1016/j.apmr.2021.02.002.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

- Rachelle Brick<sup>1</sup> · Lynne Padgett<sup>2</sup> · Jennifer Jones<sup>3</sup> · Kelley Covington Wood<sup>4</sup> · Mackenzi Pergolotti<sup>4</sup> · Timothy F. Marshall<sup>5</sup> · Grace Campbell<sup>6,7</sup> · Rachel Eilers<sup>8</sup> · Sareh Keshavarzi<sup>9,10</sup> · Ann Marie Flores<sup>11,12,13</sup> · Julie K. Silver<sup>14,15,16,17</sup> · Aneesha Virani<sup>18</sup> · Alicia A. Livinski<sup>19</sup> · Mohammed Faizan Ahmed<sup>3</sup> · Tiffany Kendig<sup>4</sup> · Bismah Khalid<sup>20</sup> · Jeremy Barnett<sup>21</sup> · Anita Borhani<sup>3</sup> · Graysen Bernard<sup>3</sup> · Kathleen Doyle Lyons<sup>22</sup>
- <sup>1</sup> Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20850, USA
- <sup>2</sup> VA Central Office, Health Services Research and Development, 1100 1st St NE, Suite 6, Washington, DC 20002, USA
- <sup>3</sup> Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, University Health Network, 200 Elizabeth Sr. PMB-B-045, Toronto, ON M5G 2C4, Canada
- <sup>4</sup> ReVital Cancer Rehabilitation, Select Medical, 4714 Gettysburg Road, Mechanicsburg, PA 17055, USA
- <sup>5</sup> Ivy Rehab Network, 1311 Mamaroneck Ave, Suite 140, White Plains, NY 10605, USA
- <sup>6</sup> Duquesne University School of Nursing, 600 Forbes Avenue, Pittsburgh, PA 15282, USA
- <sup>7</sup> Department of Obstetrics, Gynecology, and Reproductive Sciences and UPMC Hillman Cancer Center at UPMC Magee, School of Medicine, University of Pittsburgh, 300 Halket Street, Pittsburgh, PA 15213, USA
- <sup>8</sup> Department of Occupational Therapy, School of Health and Rehabilitation Sciences, University of Pittsburgh, Bridgeside Point I, 100 Technology Drive, Pittsburgh, PA 15219, USA
- <sup>9</sup> Department of Biostatistics, Princess Margaret Cancer Center, 610 University Ave, Toronto, ON, Canada
- <sup>10</sup> Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, ON, Canada
- <sup>11</sup> Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA

- <sup>12</sup> Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine, Northwestern University, 645 North Michigan Avenue, 11th Floor, Chicago, IL 60611, USA
- <sup>13</sup> Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, 645 North Michigan Avenue, 11th Floor, Chicago, IL 60611, USA
- <sup>14</sup> Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA
- <sup>15</sup> Massachusetts General Hospital, 55 Fruit Street, Boston, MA, USA
- <sup>16</sup> Brigham and Women's Hospital, 55 Fruit Street, Boston, MA, USA
- <sup>17</sup> Spaulding Rehabilitation Hospital, 55 Fruit Street, Boston, MA, USA
- <sup>18</sup> Department of Rehabilitation Services, Northside Hospital, 1000 Johnson Ferry Road, Atlanta, GA 30342, USA
- <sup>19</sup> National Institutes of Health Library, Office of Research Services, OD, NIH, MSC 1150, 10 Center Drive, Bethesda, MD 20892, USA
- <sup>20</sup> Department of Occupational Science & Occupational Therapy, University of Toronto, 500 University Avenue, Toronto, ON M5G 1VT, Canada
- <sup>21</sup> George Washington University School of Medicine and Health Sciences, 2300 I St. NW, Washington, DC 20052, USA
- <sup>22</sup> Department of Occupational Therapy, MGH Institute of Health Professions, Charlestown Navy Yard, Building 79/96, 79 13th Street, Boston, MA 02129, USA